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 i 
ABSTRACT of THESIS 
 
During my PhD I worked with the group of Professor Severo Salvadori, I have 
investigated opiod system involved in the pain transmission, in particular MOP and 
NOP receptors. Presently various external opiates are administered like morphine 
for analgesic therapy, but they have a limit for clinical usefulness, because their 
tendency is to produce tolerance and dependence. The main project aim is to 
synthetize peptides bivalent ligands characterized by a NOP and MOP substrate 
with the deal to reduce the typical side effects of the current therapy. 
In order to obtain this peptide bivalent ligand was planned chemical strategies able 
to give them, in particular it was used Thio-Michael reaction and Thiol-ene 
reaction. Each reaction allows the introduction of the specific features into MOP 
pharmacophore and NOP pharmacophore involved in the reaction. 
Thio-Michael has allowed to obtain two peptides bivalent ligands: the first is 
characterized by a MOP pharmacophore as dermorphin functionalized with a Lysin 
with a maleimide function in lateral chain in C-terminal portion able to interact with 
a NOP pharmacophore as N/OFQ functionalized with a Cysteine in position 18 in 
order to afford the bivalent ligand. The second one is represented by a MOP 
pharmacophore as hexapeptide N-terminal of dinorphin with a Lysin with a 
maleimide function in lateral chain in position 8 able to react with a NOP 
pharmacophore as N/OFQ functionalized like previously seen in order to yield the 
bivalent ligand. The requirement to afford a good bivalent ligand is to maintain in 
vivo an equipotency between the substrate MOP and NOP. Both are been tested 
in vitro through the analysis of the intracellular calcium mobilization, compared to 
standard endogenous ligands, to observe the activity of the two pharmacophores 
inside the ligand with receptors transfected in CHO cells. Currently studies are 
underway in vitro tissues. The tests are performed from the group of Dr Girolamo 
Calò of Ferrara University. 
Thiol-ene reaction has not been successful to obtain peptide bivalent ligand, for 
these reasons it is decided to start an initial methodological study about Thiol-ene 
reaction. The aim was to understand the influence of the side chains of the 
aminoacids adjacent to the Cysteine, which aminoacid involved in the reaction. 
It was synthetized pentapeptades prototype with the introduction in position 3 and 
4 different aminoacids with side chains variable to assess whether some of these 
are involved in side reactions sequence dependent. As alkene substrate it was 
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used an olefin, such as the allyl-glucose. The peptides were analyzed by NMR in 
order to evaluate any changes of the chemical shift in the case of no success of 
reaction. Variable aminoacids are been investigated with characteristics 
hydrophilic, acidic and aromatic. All reactions tested have given the product of 
Thiol-ene and its byproduct sulfoxide. 
 
I spent 11 months of my PhD at Aberdeen University in the group of Professor 
Matteo Zanda and I worked in collaboration with Dr John Barrow in a study 
regarding the analysis of change of conformation of particular promoters through 
gel-based assay (EMSA). In particular the attention was focused on insulin-linked 
polymorphic region (ILPR) that is a regulatory sequence located upstream of the 
human insulin gene. It is characterized by multiple repeats of consensus sequence 
rich in guanine residues able to assume a particular conformation called G-
quadruplex. DNA complex is stabilized by some cations and small molecules. This 
peculiar structure is very important in the complex system of the activation of 
insulin gene expression.  
Since insulin is directly related to the pathogenesis of diabetes, the potential 
regulatory role of the G-quadruplex in the insulin expression has received close 
attention. 
The main project aim is to alter the functionality of the ILPR, and subsequently 
alter INS gene expression using small molecules as ligands that will bind to and 
regulate the ILPR.  
The project was developed in different steps:  
 Analysis of the appropriate concentration of oligonucleotides to proceed 
with the EMSA assay;  
 Investigation of molecules known in literature and commercially available to 
have a good ability to stabilize G-quadruplex; 
 Synthesis of a new compound triazine derivate to enhance the binding and 
stabilize the DNA complex.  
The small molecules chosen have shown a stabilization of G-quadruplexes in line 
with the data in literature. These data are also confirmed by CD analysis did from 
Glasgow University. The new triazine synthetized was only tested with EMSA 
assay and it has shown a slight ability to interact with the G-quadruplex. CD 
analysis of the new compound are under study. 
 
 iii 
RIASSUNTO della TESI 
 
Durante il mio periodo di dottorato ho collaborato con il gruppo di ricerca del 
Professor Severo Salvadori e il mio progetto di ricerca si è svolto nell’ambito dei 
recettori oppioidi coinvolti nel sistema di trasmissione del dolore, in particolare i 
recettori NOP e MOP. Attualmente in terapia analgesica vengono somministrati 
oppiacei come la morfina, che presentano dei limiti dal punto di vista clinico in 
quanto a lungo termine inducono fenomeni di tolleranza e dipendenza. L’obiettivo 
del progetto di ricerca è di sviluppare molecole peptidiche bivalenti caratterizzate 
sia da un farmacoforo NOP sia da un farmacoforo MOP per poter ridurre questi 
effetti collaterali.  
Per ottenere questo tipo di molecole peptidiche bivalenti sono state pianificate due 
strategie sintetiche in grado di permettere di legare i due substrati scelti, le 
reazioni utilizzate sono la reazione di Thio-Michael e la reazione di Thiol-ene. 
La reazione di Thio-Michael ci ha permesso di ottenere due ligandi bivalenti: il 
primo è caratterizzato da un farmacoforo quale una dermorfina funzionalizzata al 
C-terminale con una Lisina modificata in catena laterale con una maleimmide in 
grado di poter reagire con il farmacoforo NOP, N/OFQ (1-17) modificata al C-
terminale con l’introduzione di una Cisteina. Nel secondo ligando si è utilizzato 
come farmacoforo MOP l’esapeptide N-terminale della dinorfina funzionalizzata 
con una Lisina portante in catena laterale la funzione maleimmidica in grado di 
reagire con il substrato NOP di elezione descritto prima. Il requisito fondamentale 
per avere un buon ligando bivalente prevede che ci sia una potenza paragonabile 
in vivo tra i due recettori NOP/MOP. Entrambi sono stati testati in vitro con il test di 
mobilizzazione del calcio intracellulare su cellule CHO in cui sono stati transfettati i 
recettori di interesse, attualmente sono in corso studi in vitro su tessuti. I test sono 
stati fatti presso il Dipartimento di Farmacologia del Dr Girolamo Calò 
dell’Università di Ferrara. 
La reazione di Thiol-ene ha portato a degli insuccessi nel raggiungere il nostro 
scopo di creare molecole bivalenti peptidiche. Per questo motivo è stato intrapreso 
uno studio metodologico più approfondito della reazione in campo peptidico. 
Sono stati sintetizzati dei pentapeptidi prototipo modelli con sostituzioni puntiformi 
in posizioni 3 e 4 adiacenti alla Cisteina, quale aminoacido coinvolto nella 
reazione. In questo studio sono stati analizzati con la spettroscopia NMR 
pentapeptidi aventi aminoacidi aromatici, idrofilici ed acidi in modo da poter 
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identificare tutti i chemical shift dei protoni e dei carboni e in caso di insuccesso 
della reazione identificare le reazioni collaterali. Come substrato olefinico è stato 
utilizzato principalmente un allil-zucchero. 
Tutti gli aminoacidi studiati hanno dato un esito positivo alla reazione formando sia 
il prodotto di tiolene sia un sottoprodotto rappresentato dal solfossido. 
 
Successivamente ho trascorso 11 mesi del mio dottorato presso l’Università di 
Aberdeen nel gruppo di ricerca del Professor Matteo Zanda e sono stata coinvolta 
in un progetto di collaborazione con il Dr John Barrow. Il progetto ha riguardato lo 
studio dei cambiamenti di conformazione assunti da particolari promotori 
attraverso analisi di elettroforesi su gel (EMSA). In particolare il promotore di 
interesse è stato ILPR quale acronimo di insulin-linked polymorphic region che è 
una sequenza regolatoria collocata a monte del gene insulina umano. È 
caratterizzato da regioni ricche di guanina che sono in grado di formare particolari 
complessi conosciuti come G-quadruplex. Quest’ultimo è coinvolto nel complesso 
meccanismo di attivazione dell’espressione del gene insulina per cui in caso di 
sfaldamento di questa struttura si ha conseguentemente una irregolare attivazione 
del gene e correlato diabete. In letteratura è noto che questo complesso può 
essere stabilizzato e regolato da cationi e piccole molecole. 
L’obiettivo principale del progetto è di poter regolare il promotore ILPR e 
conseguentemente l’espressione genica dell’insulina utilizzando ligandi in grado di 
poterlo stabilizzare.  
Il progetto è stato sviluppato in diversi step: 
 Studio di appropriate concentrazioni di oligonucleotidi per poterli analizzare 
con EMSA test; 
 Studio di molecole commerciali note in letteratura come stabilizzati di G-
quadruplex; 
 Sintesi di un composto derivato triazinico in grado di interagire con il 
complesso G-quadruplex e stabilizzarlo. 
Le molecole commerciali investigate e le analisi CD (svolte presso l’Università di 
Glasgow) hanno confermato i dati presenti in letteratura. Il nuovo derivato 
triazinico ha mostrato leggera attività sul G-quadruplex, ma i dati CD sono in 
questo momento in corso di studio. 
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 1 
ABBREVIATIONS 
Ac acetyl; 
AVA 5-aminovaleric acid; 
Bn benzyl; 
Boc di-tert-butyl dicarbonate; 
bp base pairs; 
Cu-APC anionic copper phthalocyanine; 
DCM or CH2Cl2 dichloromethane; 
Dde 1-(4,4-dimethyl-2,6- dioxacyclohexylidene)ethyl; 
ddH2O double distilled water; 
DIPCDI N,N'-diisopropylcarbodiimide; 
DMEA dimethylethanolamine; 
DMF dimethylformamide; 
DMSO dimethyl sulfoxide; 
DPAP 2,2-dimethoxy-2-phenylacetophenone; 
EDTA ethylenediaminetetraacetic acid; 
EMSA electromobility shift-assay; 
Et ethyl; 
Et3SiH triethylsilane; 
Fmoc fluorenylmethyloxycarbonyl; 
G4 G-quadruplex or G-tetraplex or G-tetrad; 
h hour; 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); 
HOBt hydroxybenzotriazole; 
i-Pr isopropyl; 
i.c.v. intracerebroventricular injection; 
i.t. intrathecal injection; 
ILPR insulin-linked polymorphic region; 
INS insulin gene; 
KMnO4 potassium permanganate: 
min. minutes; 
N/OFQ nociceptin or orphanin FQ; 
o.n. over night; 
Oxyma Pure ethyl 2-Cyano-2-(hydroxyimino)acetate; 
Pmc 2,2,5,7,8-pentamethyl-chroman-6-sulphonyl; 
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Pt petroleum; 
r.t. room temperature; 
SPPS Solid Phase Peptide Synthesis; 
TBE tris/Borate/EDTA; 
tBu tert- butyl; 
TFA trifluoroacetuc acid; 
THF tetrahydrofuran; 
TMS ethynyltrimethylsilane; 
tr retention time; 
Trt tripheylmethyl; 
WSC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; 
Y yield; 
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INTRODUCTION 
 
1.1 Pain  
The prevalence and cost of pain is a major physical and mental health care 
problem from the past two decades. The pain is a symptom of suffering not 
classifiable and it has a degree of subjective effect due to variable human 
sensitivity. The pain can be assessed as acute pain or chronic pain.  
Acute pain begins suddenly and is usually the individual feels a strong warning of 
disease or a threat to the body. It can be due to many events, like eg surgery, 
labor and childbirth, broken bones. Ordinarily acute pain may be mild or it may be 
more severe, but it does not last longer than six months and it disappears when 
the underlying cause of pain has been treated or has healed. Unrelieved acute 
pain, however, may lead to chronic pain. 
Chronic pain persists longer than 3 months, often despite the fact that an injury 
has healed. Pain signals remain active in the nervous system for weeks, months, 
or years. It is characterized from physical effects like muscles problems, limited 
mobility, lack of energy and changes in appetite and/or emotional effects include 
depression, anger, anxiety, and fear of re-injury. Common chronic pain complaints 
include: headache, low back pain, cancer pain, arthritis pain, neurogenic pain, 
psychogenic pain. Chronic pain may have started from an initial trauma/injury or 
infection, however, some people suffer of this in the absence of any past injury or 
evidence of body damage1. 
The pain appears to be a cause of social disability and for this reason there is a 
common scientific interest to assess the appropriate treatment for its resolution. 
Endogenous opioids exhibit their activity through an interaction with specific 
receptors that play a crucial role in several physiological functions such as 
analgesia, respiratory depression, feeding, release of certain hormones (eg 
corticosterone and growth hormone) and mood elevation.  
The introduction of drugs able to interact with the opioid receptor system may 
allow a physiological and multifunctional control. Various external opiates are 
administered like morphine for analgesic therapy, they interact with the complex 
system of endogenous opioids and unfortunately they also produce its side effects. 
The limit of the clinical usefulness of these drugs is their tendency to produce 
tolerance and dependence. The tolerance induces a need, during a chronic drug 
                                                        
1
 Pain Management Health Center, WebMD. http://www.webmd.com/pain-management/. 
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exposure, to increase the amounts of it to obtain the original effect. The related 
phenomenon of dependence arises like a physical or psychological withdrawal 
syndrome upon its removal and it is an important ability of these kinds of drugs. 
The phenomena of opiate tolerance and dependence are intensively studied and 
the proposal, in this project, is to design a drug able to contain the specific 
characteristics inside one molecule and to decrease these fundamental problems2. 
 
1.2 Opioid receptor 
Opiates operate through specific receptors located in the CNS, first identified in 
1973. They are used therapeutically to raise the threshold of perception of pain. 
Pharmacological and biochemical evidence suggest the existence of four major 
classes of opioid receptors: μ, δ, κ and ORL-1, respectively called MOP, DOP, 
KOP and NOP. The opioid receptors are metabotropic receptors structurally 
correlated to rhodopsin, characterized by 7 domains transmembrane (TM) whose 
intracellular loops are coupled to proteins belonging to G-protein family. 
Guanine nucleotide binding proteins (G proteins) are heterotrimers, made up of 
three distinct subunits , ), which bind a large number of receptors to a variety 
of effects3. 
There are many combinations of  with unique functional characteristics. The 
activity G-protein oligomer is attributed to the  subunit, an enzyme having 
intrinsic GTPase capacity. Agonist binding to a receptor protein induces a series of 
events: dissociation of the-subunit, which is complexed to , binding of GTP to 
the -subunit and its activation and separation of the G-protein from the subunits 
. The link between GTP and Gαi produces an inhibition of adenylate cyclase to 
decrease a cAMP levels (Second Messenger), which produces a reduction in the 
cell voltage of the current dependent, which achieves negative values, increasing 
the excitability threshold neurons. Adenylyl cyclases are a family of enzymes, 
which modulates ATP to cyclic adenosine monophosphate (cAMP), an intracellular 
signalling molecule. Cyclic AMP activates several cAMP-dependent protein 
kinases, which control numerous events through phosphorylation. The reduction of 
cAMP also arouses a hypofunction of PKA (protein kinases cyclic AMP 
dependent) with a decrease in the release of excitatory neurotransmitters from 
nociceptive fibers (eg glutamate, substance P). 
                                                        
2
 L. M. Harrison, A. J. Kastin, J. E. Zadina, Peptides, (1998), 19, 1603–1630. 
3
  K. M. Standifer, G. W. Pasternak, Cell. Signal., (1997), 9, 237–248). 
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The cell hyperpolarization is also due to the action of G subunits.  
It seems that these are at the basis of the mechanism that leads to modulation of 
channel proteins of Ca2+ and K+. The binding of the receptor with the agonist mean 
the opening of potassium channels by inducing a hyperpolarization of membranes 
and inhibition of calcium conductance with the consequent reduction of 
neurotransmitter release at the synaptic level. This receptor status is usually 
reversible. When the biological action was explicated, G-GTP is hydrolyzed to 
GDP and G-subunit restores the initial trimer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Receptors coupled to G-proteins GPCR). 
When the receptor binds its ligand, stimulates the exchange of GDP for GTP by the  subunit of the trimeric G 
protein, which moves away from the  complex and interacts with an effector, initiating the cascade of 
intracellular signals. Subsequently, the  subunit hydrolyzes the GTP into GDP, returning to a non-active 
conformation, which is associated again to the  complex. 
 
Studying the expression of mRNAs coding for the opioid receptors has been 
possible to identify the location of the various receptors. They are expressed at the 
level of the central nervous system (CNS) regions of the midbrain, diencephalon 
and telencephalon and spinal cord. 
MOP and KOP receptor-like immunoreactivity is widely distributed across 
gastrointestinal regions: the stomach, duodenum, ileum, proximal and distal colon, 
these opioids may regulate gastrointestinal function 4 . The DOP receptor is 
                                                        
4
 D. Bagnol, A. Mansour, H. Akil, S. J. Watson, Neuroscience, (1997), 81, 579–591. 
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concentrated in neurons, myenteric and submucosal ganglia. NOP receptors are 
located in intestine, vas deferens, liver and spleen5. The endogenous ligands for 
these receptors are peptides of different lengths characterized by a N-terminal 
portion organized in a similar way.  
In figure 2 there are the primary sequence of -endorphin, a MOP endogenous 
ligand, the enkephalins, the DOP endogenous ligands, dynorphin, a KOP 
endogenous ligand and nociceptin/orphanin FQ (N/OFQ) a NOP receptor 
endogenous ligand. 
 
-Endorphin: H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val- 
Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu-OH 
Met-Enkephalin: H-Tyr-Gly-Gly-Phe-Met-OH 
Leu-Enkephalin: H-Tyr-Gly-Gly-Phe-Leu-OH 
Dynorphin A: H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp- 
Asn-Gln-OH 
Nociceptin or orphanin FQ (N/OFQ): H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-
Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln-OH 
 
Figure 2: Primary aminoacid sequence of physiological ligands of opioid receptors MOP, DOP, KOP and 
NOP. 
 
The N-terminal portion Tyr (or Phe)-Gly-Gly-Phe, highlighted in red, is the part 
defined message domain and it is responsible for the activation of the receptor 
while the C-terminal portion is involved in receptor selectivity and it is defined 
address domain. In 1997 two new peptides very selective against the MOP 
receptor were discovered: Endomorphin I (H-Tyr-Pro-Trp-Phe-NH2) and 
Endomorphin II (H-Tyr-Pro-Phe-Phe-NH2), whose precursor has not yet been 
identified6. From the point of view of the evolution gene, the nociceptin belongs to 
the same family of other opioid ligands, and also the NOP receptor has high 
sequence homology with the opioid receptors7, however from the functional point 
of view the NOP receptor does not bind opioid ligands with high affinity and in the 
same way the nociceptin does not interact with opioid receptors with high affinity. 
Drugs able to activate the MOP receptor are used from years for the pain therapy. 
MOP agonists have two important actions related to motivational systems:  
                                                        
5
 J. B. Wang, P. S. Johnson, Y. Imai, A. M. Persico, B. A. Ozenberger, C. M. Eppler, G. R. Uhl, FEBS Letters, (1994), 348, 
75-79. 
6
 J. E. Zadina, L. Hackler, L.-J. Ge, A. J. Kastin, Nature, (1997), 386, 499- 502. 
7
 C. W. Stevens, Front Biosci, (2009), 14, 1247-1269. 
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(1) suppress the pain and (2) promote the pursuit of pleasure.  
Their most important clinical application is for pain relief. Indeed, the MOP 
agonists are the most powerful analgesics currently available. Their therapeutic 
efficacy undoubtedly derives from the fact that they have numerous inhibitory 
actions against the pain. They directly inhibit pain transmitted by neurons in the 
periphery and CNS. 
They also act on the descending pain modulatory circuits that control pain 
transmission at the spinal cord level. In addition, MOP agonists induce significant 
positive motivational effects. A circuit that includes the dopaminergic neurons in 
the ventral tegmental area of the midbrain mediates these effects and their 
connections with the limbic regions, involving the sub-cortical areas taking the 
nucleus accumbens and the amygdala. For this reason the identification of new 
analgesic drugs without the side effects of opioids is the interest of today. It has 
recently been approved for intrathecal infusion a new analgesic drug called 
Ziconotide8. This molecule is a cyclic peptide derived from a shell of the genus 
Conus Magus9. Ziconotide is a peptide that blocks the entry of calcium in the 
neuronal voltage-gated calcium channels through N-type, preventing the 
conduction of nerve signals and decreasing the pain perception. However, 
Ziconotide is a small therapeutic window, because it has the considerable side 
effects in the CNS and for this the treatment is used for a small group of people 
with severe chronic pain. Also the peptidergic system NOP receptor/N/OFQ is 
implicated in the modulation of the painful stimulus and recent evidence suggests 
that this receptor system may be used to induce analgesia without causing 
dependence10. Furthermore, in vivo studies on non-human primate have shown 
that spinal administration of an analogue of N/OFQ 100-fold more potent called 
UFP-112 is able to evoke analgesic effects like those obtained with morphine11 
(Figure 3). 
 
 
 
 
                                                        
8
 J. E. Pope, T. R. Deer, Expert Opinion on Pharmacotherapy, (2013), 14, 957-966. 
9
 D. R. Hillyard, V. D. Monje, I. M. Mintz, B. P. Bean, L. Nadasdi, J. Ramachandran, G. Miljanich, A. Azimi-Zoonooz, J. M. 
McIntosh, L. J. Cruz, J. S. Imperial, B. M. Olivera, Neuron, (1992), 9, 69-77). 
10
 A. P. Lin, M.-C. Ko, ACS Chem. Neurosci., (2013), 4, 214–224. 
11
 E. Hu, G. Calò, R. Guerrini, M.-C. Ko, Pain, (2010), 148,107-113. 
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Figure 3: Comparison of analgesic effects produced by administration i.t. UFP-112 and morphine. 
 
NOP agonist does not produce itching, typical side effect of MOP ligands regularly 
administered systemically. It has been shown that the co-administration of doses 
of intrathecal morphine (usually alone is an ineffective dose) and UFP-112 is 
capable of generating a robust analgesic effect (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Analgesic effect due to co-administration i.t of UFP-112 and morphine. 
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These data suggest that a bivalent ligand is able to activate both NOP/ MOP 
receptors and it could be useful as analgesic cord. In the literature there are 
numerous examples of bivalent ligands capable of interacting with opioid 
receptors12. Furthermore, there are also extensive evidence on the existence of 
homo-and heterodimeric forms of GPCRs 13 . The dimerization appears to be 
important for the maturation of receptor 14 . Furthermore it was shown that 
dimerization could lead to the formation of new species potentially 
pharmacological target of innovative drugs. Recent observations highlight that the 
dimerization of receptors between different opioids or opioid and non-opioid is 
involved in the in vivo effects mediated from opioid and it plays an important role in 
evoking biological phenomena complexes such as the development of tolerance to 
morphine15. From scientific literature there are several examples of molecules able 
to interact with dimeric opioid receptors. One of the latest examples reported by 
Portoghese et al. proves that the compound MDAN-21 (MOP agonist/DOP 
antagonist) has a potent central analgesic activity without inducing tolerance12. 
This event could be due to lack of receptor internalization generated by co-
stimulation of MOP and DOP heterodimeric receptors (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
12
 A. S. Yekkirala, A. E. Kalyuzhny, P. S. Portoghese, ACS Chem. Biol., (2010), 8, 1412–1416. 
13
 V.Casadó, A. Cortés, J. Mallol, K. Pérez-Capote, S. Ferré, C. Lluis, R. Franco, E. I. Canela, Pharmacology & 
Therapeutics, (2009), 124, 248–257. 
14
 S. Bulenger, S. Marullo, M. BouvierTrends, Pharmacol. Sci, (2005), 26,131–137. 
15
 R. Rozenfeld , N. S. Abul-Husn, I. Gomez, L. A. Devi, Sci World J., (2007), 7, 64–73. 
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Figure 5:  Scheme of the molecular mechanism proposed for the inhibition of internalization by a bivalent 
ligand opioid. 
 
Thank to these knowledge homo- and heterodimers of opioid receptors could 
represent a novel therapeutic target for the pain therapy. In literature, there are 
some data that support the possible existence of MOP/NOP heteromeric receptor. 
For example, the i.c.v. administration of a selective NOP antagonist increases the 
analgesia induced by a MOP agonist and it produces an antinociceptive effect 
resistant to naloxone16. The contribution of these functional interactions in dimeric 
receptors was tested with recombinant receptors expressed in HEK293 cells17. 
Co-immunoprecipitation studies have shown that MOP and NOP receptors could 
be isolated in complexes that interact18 19. In cells that co-expressing MOP and 
NOP receptors, the treatment with the NOP agonist, nociceptin, stimulates the 
internalization of MOP. In a similar way the treatment with MOP agonist, DAMGO, 
due to the internalization of the NOP18. In vitro assays on cells who co-expressing 
MOP and NOP receptors show that the presence of the MOP receptor attenuates 
the inhibition of N channels of calcium induced by N/OFQ, while the activation of 
MOP receptor promotes the internalization of calcium channels only in the 
presence of the NOP receptor21.  
In the figure below it is shown the schematic structure of a bivalent molecule. 
 
                                                        
16
 G. Calo', R. Guerrini, A. Rizzi, S. Salvadori, D.Regoli, British Journal of Pharmacology , (2000), 129, 1261- 1283. 
17
 H.-L. Wang, C.-Y. Hsu, P.-C. Huang, Y.-L. Kuo, A. H. Li, T.-H. Yeh, A.-S. Tso, Y.-L. Chen, Journal of Neurochemistry, 
(2005), 92, 1285-1294. 
18
 R. M. Evans, H. You, S. Hameed, C. Altier, A. Mezghrani, E. Bourinet, G. W. Zamponi, J. Biol. Chem., (2010), 285, 1032-
1040. 
19
 Y. X. Pan, E. Bolan, G. W. Pasternak, Biochem. Biophys. Res. Commun., (2002), 297, 659–663. 
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Figure 6: Scheme of a bivalent ligand. 
 
For the design of this structure is essential to consider several parameters: the 
choice of the pharmacophore, the point of attachment of the linker and length of 
the spacer. The pharmacophore contains the structural information required for the 
binding and activation (or block) of the receptor and it must have an attachment 
point for the linker that do not compromise the desired biological activity. The 
spacer may have different length, several chemical compositions and it may be 
rigid or flexible. The possibility to modulate the length of the spacer makes 
possible the synthesis of bivalent molecules that they may have suitable 
characteristics to interact with dimeric receptor forms. At this regard, in literature 
there are many indications relative to the length of the spacer like a critical factor 
for the potency of the ligand20 (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
20
 J.  Shonberg, P. J. Scammells, B. Capuano, Chem. Med. Chem., (2011), 6, 963-974. 
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Figure 7: Graph that highlights the relationship between potency and length of the spacer that connect the 
two pharmacophores. 
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2. AIM OF THE PROJECT 
 
In this project it has tried to develop bivalent ligands to use them as a spinal 
analgesic drugs. The project was created with the idea to introduce in a single 
molecule both a MOP pharmacophore and a NOP pharmacophore. 
These ligands have as a NOP substrate N/OFQ and variable MOP substrate. 
 
 
 
 
 
 
 
Figure 8: Scheme of a bivalent ligand design. 
 
In order to exploit the synergism of enhancement analgesic highlighted with the  
co-administration in spinal cord in the non-human primate11 of NOP agonist and a 
MOP agonist, one of the pharmacological characteristics desired for these bivalent 
ligands is NOP/MOP equipotency. 
It was evaluated several possible MOP ligands, known in literature, to bind to the 
NOP ligand defined. It is planned to use the following substrates MOP: dermorphin 
changed in C-terminal with a Lysine (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-Lys-NH2), 
endomorphin I (H-Tyr-Pro-Trp-Phe-NH2), the endogenous opioid tetrapeptide (H-
Tyr-Gly-Gly-Phe), the endogenous opioid tetrapeptide modified in C-terminal with 
a Lysine (H-Tyr-Gly-Gly-Phe-Lys) and finally the N-terminal hexapeptide of 
dynorphin (H-Tyr-Gly-Gly-Phe-Leu-Arg) (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
	
NOP MOP 
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Figure 9: Opioid pharmacophores considered in this study. 
 
These peptides prototype are functionalized to the carboxylic portion with spacer 
of different length and chemical composition having an acetylated Lysine side 
chain as the last amino acid of the sequence. 
In particular, it is chosen a spacer consisting of glycine (Gly and Gly-Gly), amino 
valeric acid (AVA) and one spacer polyoxyethylene (O2Oc) (Figure 10). 
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Figure 10: List of spacers and functionalization of pharmacophores in the C-terminal portion. 
 
The acetyl group on the side chain of Lysine has the only aim to mimic the 
maleimide function that will be used to generate the bivalent ligands. 
The chemistry strategy used to generate the bivalent ligands provides for the 
synthesis of the two NOP and MOP pharmacophores suitably functionalized, their 
purification and finally their conjugation through the use of a highly chemoselective 
reaction, such as Thio-Michael reaction21. My research group has already used 
this reaction for the synthesis of similar molecules and it is characterized by: high 
chemoselectivity, speed of reaction, almost quantitative yields and mild reaction 
conditions. The chemical strategy requires the functionalization of the C-terminal 
N/OFQ with a Cysteine residue [Cys18] N/OFQ-NH2, synthesis that was made of 
medium scale (hundreds of mg). 
After pharmacological evaluation of the designed MOP pharmacophore, the 
compound that has showed the most suitable characteristics it was resynthesized 
and functionalized side chain of the Lysine with a maleimide group that allows the 
easy conjugation with [Cys18] N/OFQ-NH2 according to the general pattern: 
 
 
 
 
 
 
 
 
 
                                                        
21
 D. P. Nair, M.Podg rski,  . Chatani, T. Gong, .  i, C. R. Fenoli, C. N. Bowman, Chem. Mater., (2014), 26, 724−744. 
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Figure 11: General scheme adopted for the synthesis of a bivalent ligand NOP/MOP. 
 
To obtain bivalent ligands it was also planned to use a second synthetic strategy, 
such as the Thiol-ene reaction. There are many evidence in literature that confirm 
the availability of this reaction to connect two peptides22 23. It allows high efficiency 
and orthogonality of the reaction with bulky substrates. In this study Thiol-ene 
reaction provides to link two pharmacophores one MOP and one NOP suitably 
functionalized in C-terminal position.  
 
 
 
 
 
 
 
 
 
                                                        
22
 A. A. Aimetti, K. R. Feavera,  K. S. Anseth, Chem. Commun., (2010), 46, 5781–5783.   
23
 A. Dondoni, A. Massi, P. Nanni, A. Roda, Chem. Eur. J., (2009), 15, 11444 – 11449.     
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The chemical approach permits the introduction of thiols with a Cys in the C-
terminal of NOP pharmacophore (N/OFQ) and a wide variety of unsaturated 
moiety in the C-terminal MOP pharmacophore. Below it is shown a scheme of 
Thiol-ene strategy (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: General scheme used for Thiol-ene strategy. 
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3. DISCUSSION 
 
In this thesis the synthetic strategy to obtain NOP/MOP agonists bivalent ligands 
with natural peptides was investigated. These molecules were done applying a 
convergent synthetic approach. Firstly the NOP/MOP prototype peptides were 
synthesised, purified separately and than linked together using chemoselective 
reactions. Infact the presence in the peptides sequence of many functional groups 
as aminoacid side chains imposes the use of highly chemoselective reactions. The 
chemoselective reactions selected were Thio-Michael and Thiol-ene strategies. 
The synthetic scheme adopted for the synthesis of bivalent ligand is reported in 
figure 13. 
 
 
 
 
 
 
 
 
Figure 13: Chemical strategies to build bivalent ligand. 
The strategies chosen have a peculiar characteristics, both belong from the “Click-
chemistry” reaction family. In 2001, Sharpless et al. have described a new concept 
for conducting organic reactions with the introduction of reaction with highly 
selectivity, simple orthogonals that give not side products and that they form 
heteroatom-linked molecular systems with high efficiency under an assortment of 
mild conditions24. Many reactions belong to this class and they have in common 
the following characteristics: 
i. high yields and by-products (if any) are removed by nonchromatographic 
processes; 
ii. regiospecificity and stereospecificity; 
iii. more or less insensible to oxygen or water; 
iv. mild reaction conditions (solventless or aqueous); 
v. orthogonality with other common organic synthesis reactions; 
vi. wide range of available starting compounds. 
                                                        
24
 C. E. Hoyle, C. N. Bowman, Angew. Chem. Int. Ed., (2010), 49, 1540-1573. 
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All compounds were evaluated in tests carried out on intracellular calcium 
mobilization CHOhMOP + Gαqi5 cells and their activity was compared to standard 
MOP ligands as dermorphin, Leu-enkephalin and endomorphin 1. 
The bivalent compounds  (Figure 18 and 22) were also tested on cells CHOhNOP + 
Gαqi5 and their activity were compared to that of the endogenous ligand for the 
NOP N/OFQ. In these cells, thanks to the use of the chimeric G protein (see 
materials and methods), the activation of the receptor leads to increased levels of 
intracellular calcium. 
Standard ligands - In CHOhMOP + cells Gαqi5 MOP receptor standard ligands 
dermorphin, Leu-enkephalin and endomorphin 1 have stimulated the release of 
intracellular calcium in a concentration-dependent effects producing maximum of 
177 ± 24, 144 ± 14 and 209 ± 3. 
For the ligand was calculated dermorphin a pEC50 of 8.30 while for Leu-enkephalin 
and endomorphin 1 were estimated pEC50 values of 7.26 and 8.00 (Table 1 and 
figure 14, left panel).  
In cells CHOhNOP + Gαqi5 the natural peptide N/OFQ was able to increase the levels 
of intracellular calcium in a concentration-dependent, showing a maximal effect of 
224 ± 1 and a pEC50 of 9.95 (Figure 14, right panel). 
The results obtained with the standard ligands are similar with previously reported 
data in the literature. 
 
Figure 14: Test of intracellular calcium mobilization of cells CHOhMOP + Gαqi5 (left panel) and CHOhNOP + Gαqi5 
(right panel). Effect of standard agonists dermorphin, Leu-enkephalin and endomorphin 1. Data are expressed 
as mean ± e.s.m. of 4 experiments performed in duplicate. 
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3.1 Thio-Michael strategy 
 
As first approach, in particular, it was used for the goal the Thiol-maleimide 
Michael addition reaction, because it has been widely exploited in biological 
systems, primarily due to high selectivity of the Thiol-maleimide reaction in 
aqueous environments, the rapid kinetics and the stability of the thiol-maleimide 
product21. The high reactivity of C=C bond in maleimide probably causes many 
factors:  the bond angle distortion, the ring contortion and the carbonyl groups 
being in the cis-conformation25.  The thiol function can be easily introduced in a 
peptide sequence as Cys side chain while the Michael acceptor group (in general 
is an - unsatured carbonyl moiety) not present as an aminoacid side chain, but 
they can be ad hoc introduced in the peptide sequence to obtain the desired 
chemoselectivity of the linking reaction. 
Like substrates were chosen a NOP pharmacophore N/OFQ (1-17) and a MOP 
pharmacophore dermorphin conveniently functionalized see figure 15. 
 
Figure 15: Synthetic scheme of Thio-Michael reaction to build a NOP/MOP bivalent ligand 23. 
 
 
 
 
                                                        
25
 M. Li, P. De, S. R. Gondi, B. S. Sumerlin, Polym. Sci., Part A: Polym. Chem., (2008), 46, 5093-5100. 
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The first MOP pharmacophore (compound 1) synthesized is the dermorphin, a 
peptide isolated from the skin of amphibians)26 functionalized at the C-terminal 
portion by a Lysine residue (acetylated in the side chain), while NOP 
pharmacophore is performed by N/OFQ modified in C-terminus with a Cys having 
a thiol function needed to reaction10.  
Subsequently the Lysine acetylate was substituted with a maleimide function see 
figure 16 and 17. 
 
 
 
 
 
 
 
Figure 16: Structure of dermorphin sequence with Lysine acetylated in position 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Structure of dermorphin peptide sequence modified in position 8 of the Lysine side chain with the 
introduction of maleimide function(see condition in material & methods). 
 
 
The [Lys (Mal.)]8Dermorphin-NH2 (compound 1bis) was purified and than linked 
with [Cys18] N/OFQ-NH2 following the conditions described above. 
                                                        
26
 L. Negri, G. F. Erspamer, C. Severini, R. L. Potenza, P. Melchiorri, V. Erspamer, Proc. Nail. Acad. Sci. USA, (1992), 89, 
7203-7207. 
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Figure 18: Bivalent ligand NOP / MOP (compound 24) consists of the pharmacophore N / OFQ and 
compound 1 bis. 
 
The conjugation reaction is practically complete after 5-min. In Figure 19 is shown 
the HPLC chromatogram of the final product purified and its mass spectrum. 
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Figure 19: Analytical HPLC chromatogram and MS spectrum of the final compound 24. 
 
Bivalent ligand 24 – Compound 24 were tested in CHO cells stably expressing the 
MOP receptor. In these cells, compound 24 stimulates calcium mobilization in a 
concentration-dependent manner showing a pEC50 of 7.16. This value of potency 
is about 10-fold lower respect to the standard MOP reference agonist dermorphin 
(pEC50 8.30). On the contrary, in cells expressing NOP receptors, compound 24 
stimulate intracellular calcium mobilization with a pEC50 of 9.58, only 2-fold less 
active respect the natural ligand N/OFQ (pEC50 9.95). 
 
Figure 20: Test of intracellular calcium mobilization of cells CHOhMOP + Gαqi5  (left panel) and CHOhNOP + Gαqi5 
(right panel). Effect of standard agonists dermorphin, N/OFQ and of the compound 24. Data are expressed as 
mean ± e.s.m. of 4 experiments performed in duplicate. 
 
The aim of this study was to identify NOP/MOP bivalent agonist ligands able to 
stimulate in vivo both receptors with the same potency. It is known in literature that 
in vivo, dermorphin stimulates the MOP receptor with an order of potency about 
[M+2H]2+ 
[M+4H]4+ [M+3H]3+ 
[M+5H]5+ 
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100-fold higher respect in vitro assays27. To cope with this trouble it is decided to 
recognize novel MOP ligands to be combined with N/OFQ and possibly to showing 
in vivo a potency comparable to that of N/OFQ. 
As novel MOP ligands are studied the N-terminal of different MOP substrates like 
endomorphin I (H-Tyr-Pro-Trp-Phe-NH2), the endogenous opioid tetrapeptide (H-
Tyr-Gly-Gly-Phe), the endogenous opioid tetrapeptide modified in C-terminal with 
a Lysine (H-Tyr-Gly-Gly-Phe-Lys) and finally the N-terminal hexapeptide of 
dynorphin (H-Tyr-Gly-Gly-Phe-Leu-Arg).  
 
Table 1: MOP pharmacological activity obtained in the assay of calcium mobilization. 
 
New pharmacophore MOP - the activity in the test of intracellular calcium 
mobilization performed on cells CHOhMOP + Gαqi5 of the new compounds 
synthesized in this thesis is shown in Table 1. 
 
 
                                                        
27
 R. Tomatis, M. Marastoni, G. Balboni, R. Guerrini, A. Capasso, L. Sorrentino, V. Santagada, G. Caltendo, L. H. Lazarus, 
S. Salvadori, J. Med. Chem., (1997), 40, 2948-2952. 
Compound Emax
Dermorphin 177±24
Leu-enkephalin 144±14
Endomorphin 1 209±3
2
3
4
5
6 179±15
7 152±28
8
9
10
11
12 151±15
13
14
15
16
17
18 175±25
19 168±28
20 187±39
21 167±21
22 181±29
23 143±17
pEC50
H-Tyr-DAla-Phe-Gly-Tyr-Pro-Ser-NH 2
H-Tyr-Gly-Gly-Phe-Leu- NH 2
H-Tyr-Pro-Trp-Phe- NH2
H-Tyr-Pro-Trp-Phe-Lys(Ac)- NH2
Sequence
8.30 (8.09-8.52)
7.26 (6.89-7.62)
8.00(7.91-8.09)
Crc incomplete: at 10µM 117±13
H-Tyr-Gly-Gly-Phe-Lys-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Lys-Gly-Lys(Ac)- NH2
H-Tyr-Pro-Trp-Phe -Gly-Gly-Lys(Ac)- NH2
H-Tyr-Pro-Trp-Phe-O2Oc-Lys(Ac)- NH2
H-Tyr-Pro-Trp-Phe-AVA-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe- NH2
H-Tyr-Gly-Gly-Phe-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Gly-Lys(Ac)- NH2
Crc incomplete: at 10 µM 67±17
7.12 (6.82-7.42)
6.52 (5.83-7.22)
6.29 (6.04-6.54)
H-Tyr-Gly-Gly-Phe-Leu-Arg-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Gly-Gly-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-O2Oc-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe -AVA-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Lys- NH2
H-Tyr-Gly-Gly-Phe-Lys-Gly-Gly-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Lys-O2Oc-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Lys-AVA-Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Leu-Arg- NH2
Crc incomplete: at 10µM 81±1
6.10 (5.94-6.26)
Crc incomplete: at 10µM 97±6
Crc incomplete: at 10µM 43±8
Crc incomplete: at 10 µM 110±29
5.98 (5.78-6.17)
Crc incomplete: at 10 µM 141±25
Crc incomplete: at 10 µM 152±23
Crc incomplete: at 10 µM 80±14
Crc incomplete: at 10 µM 65±25
Crc incomplete: at 10 µM 132±25
Crc incomplete: at 10 µM 97±27
Crc incomplete: at 10 µM 88±13
6.84 (6.17-7.52)
6.89 (6.28-7.49)
6.52 (5.45-7.58)
H-Tyr-Gly-Gly-Phe-Leu-Arg-AVA-Lys(Ac)- NH2 6.81 (6.21-7.41)
H-Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Gly -Lys(Ac)- NH2
H-Tyr-Gly-Gly-Phe-Leu-Arg-O2Oc-Lys(Ac)- NH2
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The functionalization of the C-terminal part of the endomorphin is not tolerated.  
It is sufficient to add a lysine residue (acetylated in side chain in compound 2) to 
completely lose its biological activity. This pharmacological data agrees with 
previous works in which the modification of the C-terminal of the endomorphin is 
not well admitted28 29. The insertion of spacers of different length between the 
MOP pharmacophore and the Lysine residue (compound 3-5) is not able to restore 
the binding to the MOP receptor. Even the MOP pharmacophore Tyr-Gly-Gly-Phe 
(compound 6) as itself or by insertion of a lysine residue (compound 12) shows to 
be very sensible to the C-terminal functionalization. In fact, the reference 
sequence Tyr-Gly-Gly-Phe-NH2 has a pEC50 of 6.29 little conditioned with the 
addition of a single acetylated lysine residue (compound 7; pEC50 5.98). The 
further functionalization with spacers investigated produces the loss of activity 
(compounds 8-11). The pharmacophore Tyr-Gly-Gly-Phe-Lys-NH2 behaves in a 
similar way (compounds 13-17). The pharmacophore Tyr-Gly-Gly-Phe-Leu-Arg-
NH2 (compound 18), N-terminal portion of dynorphin, is found to be the most 
tolerant in changes in the C-terminal. Its replacement with Lys (Ac) (compound 19) 
resulted in a loss of potency of 7 times. 
The further functionalization with the spacers produces molecules able to bind and 
activate the MOP receptor and it promotes (in the case of Gly (20) Gly-Gly (21) 
and Ava (23) a significant recovery of potency compared to Tyr-Gly-Gly-Phe-Leu-
Arg-Lys (Ac)-NH2 (compound 19). These data confirm that the endomorphin is a 
MOP pharmacophore that does not tolerate alterations in the C-terminalportion of 
the molecule. Moreover, even the simple opioid message domain Tyr-Gly-Gly-Phe 
cannot be replaced in the C-terminal with a residue of Lys (Ac). It seems to be 
better accepted a free lysine side chain (compound 12) even if the subsequent 
addition of Lys (Ac) drastically reduces the potency of the peptide (compound 13). 
The C-terminal hexapeptide of dynorphin become obvious be the one that best 
admits substitutions. In fact, this hexapeptide can be considered as a Leu-
enkephalin (Tyr-Gly-Gly-Phe-Leu) with addition of Arg residue in the C-terminal. 
The further functionalization of this natural hexapeptide does not produce drastic 
loss potency suggesting that the minimum message opiod editable in the C-
terminal may be represented by simple Leu (or Met) enkephalin. This hypothesis is 
under investigation in our laboratories.  
                                                        
28
 W. X. Liu, R. Wang, Med. Res. Rev., (2012), 32, 536-580.  
29
 C.-L. Wang, C. Guo, Y.-Q. Wang, Y. Zhou, Q. Li, J.-M. Ni, R. Wang, Peptides, (2011), 32, 293–299. 
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These results suggested that the peptide H-Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Lys(Ac)-
NH2 (compound 20) it can be an efficient MOP pharmacophore to generate a new 
NOP/MOP bivalent ligand prototype. This peptide was resynthesized replacing the 
function of Lys acetylated in the side chain of C-terminal with a maleimide function 
(figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21:  Compound 20bis with a maleimide function in the side chain. 
 
Once purified, the peptide was conjugated with the [Cys18] N/OFQ-NH2 using the 
Thio-Michael addition to yield (Figure 22) compound 25. 
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Figure 22: Bivalent ligand NOP / MOP (compound 25) consists of the pharmacophore N / OFQ and 
compound 20bis. 
 
Also in this case the conjugation reaction is ended totally after 5-min. It is 
displayed the HPLC profile of the crude reaction as an example and you can see 
the full disappearance of Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Lys(maleimide)-NH2, with 
only the formation of the desired product with a molar excess 10% of [Cys18] 
N/OFQ-NH2 used to force the reaction to completeness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Analytical HPLC chromatogram of the reaction mixture [Cys
18
] N/OFQ-NH2 and compound 20bis. 
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Figure 24: Analytical HPLC chromatogram and MS spectrum of the final compound 25. 
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Bivalent ligand 25 – Compound 25 was tested on cells expressing the MOP 
receptor, compound 25 produced an increase in the levels of intracellular calcium 
in a concentration-dependent way with a potency of 6.15 and a maximum effect of 
174 ± 28. This compound proves to be about 100 times less potent than the 
standard MOP agonist dermorphin (pEC50 8.30) and nearly 100-fold less potent 
than the starting compound 20 (pEC50 6.84). In cells expressing the NOP receptor 
the derivative 25 has stimulated intracellular calcium mobilization with pEC50 of 
9.47 and a maximum effect of 221 ± 12, showing 3-fold less potent of the natural 
ligand N/OFQ (pEC50 9.95) (Figure 25). 
 
Figure 25: Test of intracellular calcium mobilization of cells CHOhMOP + Gαqi5  (left panel) and CHOhNOP + Gαqi5 
(right panel). Effect of standard agonists dermorphin, N/OFQ and of the compound 20 and 25. Data are 
expressed as mean ± e.s.m. of 4 experiments performed in duplicate. 
 
 
The difference of potency between the two pharmacophores in vitro resulted to be 
about 1000 times and therefore at list in theory, not in line with the requirement of 
NOP/MOP equipotency recommended for the development of a potential spinal 
bivalent analgesic.  
 
Compound 24 and 25 will be soon tested in vitro on tissues expressing the native 
NOP and MOP opioid receptors to determine the NOP and MOP potency.  
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3.2 Thiol-ene strategy 
 
The second approach for the synthesis of bivalent ligands was Thiol-ene reaction. 
Thiol-ene chemistry takes advantages through the addition of thiols across virtually 
any terminal -ene double bond30. Below it is displayed the reaction mechanism of 
the Thiol-ene reaction (scheme 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: General Thiol-ene coupling mechanism. 
 
In the 1938 M. S. Kharasch et al. demostrated that the addition of thiols to alkenes 
proceeds via a free-radical chain mechanism. The reaction starts by radical 
formation UV excitation of a photoinitiator or the thiol itself. After sulfenyl radical 
product reacts with the unsaturated alkene substrate in an anti-Markovnikov 
fashion to give a new carbon radical. In a second propagation step, the new 
radical that is formed, interacts with another thiol molecule to yield the thioester 
product and a new sulfenyl radical, which propagates to carry on the radical cycle. 
A variety of termination pathways are possible through a crossing between 
sulfenyl or carbon radicals. The Thiol-ene coupling reaction can be described as a 
“click” reaction in agreement to the original definition explained by Sharpless et 
al.31.  
However, despite the advantages that fit the “click” definition, there are limitations 
of this type of chemistry, which include its loss of stereospecificity, the developing 
of unwanted disulfide byproducts through radical recombination. 
The Thiol-ene reaction may be carried out in batch or in flow32.  
 
                                                        
30
 C. E. Hoyle, Polymer Preprints, (2008), 49, 155-156. 
31
 M. Kryger, Chem. 535 Seminar, (2008). 
32
 C. Wiles, P. Watts, Chem. Commun., (2011), 47,  6512–6535. 
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The difference between the two approaches are that the irradiation in batch can 
turn out to be not completely homogeneous throughout the sample. 
In this study the flow reaction exploits the technique of photolithography that is a 
system in polydimethylsiloxane with an internal volume of 10μl and a size of the 
channels of 50μm. The photoinitiator is introduced in an amount equal to 10mol%, 
the allyl-compound in excess of 3 eq. compared to the peptide in a solution of 
degassed DMF (with molar concentration in thiol approxoximately 0.05M). A 
reaction solution of 20μl is injected every minute with a syringe in an anhydrous 
environment affected by UV light of λ 365nm. 
This technique allows to:  
 radiate in a homogeneous solution;  
 control the residence time, the time which needs the first molecule      
 reaction to enter and exit from the microreactor according to this 
 relation: Vz / flow rate = reaction time (Example 10 (μL) / 20 (μl / min) = 0.5 min 
 = 30 seconds). 
The system works in optimal conditions to 1 μl/min, which corresponds to a 
residence time of 10 min. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Image of a microreactor. 
 
In order to exploit the characteristics of Thiol-ene coupling23 it decided to carry on 
this reaction with the MOP substrate and NOP substrate fittingly functionalized as 
previously reported in our laboratory studies. An enkephalin (Tyr-Gly-Gly-Phe-Gly-
NH2), functionalized at the C-terminus with a thiol function represented by Cys, 
was reacted with an olefin such as dodecene with a good outcome of the reaction.  
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Below you are illustrated spectra of analysis. 
 
Figure 27: Mass spectrum (to the left) and HPLC profile (to the right) of the adduct purified. 
 
Initially the reaction was tested using the elected pharmacophores: the bulky 
peptide NOP substrate [Cys18] N/OFQ-NH2 and the MOP substrate dermorphin 
functionalized in position 8 of C-terminal with an allyl group such as allyl-Gly 
(purchased from Sigma-Aldrich) in different concentrations of solvent. The reaction 
was done in the following condition see figure 28. 
 
Figure 28: General scheme of Thiol-ene reaction to get a bivalent ligand. 
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The tests are summarized in the table below. 
Concentration Amount Wavelength Photoinitiator Time 
Solvent Peptide eq. Alkene eq. 
  
  
  
0,5M DMF 1 1 365 nm DPAP 10 mol % 1h 
0,05M DMF 1 1 365 nm DPAP 10 mol % 1h 
0,05M DMF 1 1 365 nm DPAP 10 mol % 1h 
0,5M DMF 1 3 365 nm DPAP 10 mol % 1h 
0,5M DMF 1 4 365 nm DPAP 10 mol % 1h 
0,5M DMF 1 5 365 nm DPAP 10 mol % 1h 
0,5M DMF 3 1 365 nm DPAP 10 mol % 1h 
          
Table 2:  Different reaction conditions tested. 
 
Unfortunately, the reaction has not been successful, the only product developed 
by this reaction appears to be the dimer of [Cys]18 N/OFQ (1-17)-NH2 with a 
formation of a disulfide bridge, so this assumption it has tried to investigate what 
were the causes. Moreover in literature there are not deepened studies in the field 
of the peptides Thiol-ene reaction. 
For these reasons it was decided to start an initial methodological study about 
Thiol-ene reaction. The aim was to understand the influence of the side chains of 
the aminoacids adjacent to the Cysteine, which aminoacid involved in the reaction. 
Initially it was first synthesized a series of simple Pentapeptides model by 
introducing in position 3 and 4 aromatic aminoacids as you can see in the scheme 
below. 
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Scheme 2: List of Pentapeptides of the first series. 
 
Each peptide was subjected to a thorough analysis and identification NMR: 1H, 
13C, DEPT, COSY, HMBC, HMQC before and after (in case of failure) the reaction 
in order to observe the variations in the spectra.  
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Each peptide was reacted with the allyl-sugar with this structure: 
 
 
 
Some peptides were reacted well with Fmoc-allyl-Asp(OtBu) whose structure 
follows: 
 
 
 
 
 
 
 
 
Finally for its commercial availability has been used in some cases the dodecene 
represented below: 
 
 
 
 
The methods of synthesis of allyl-glucose and Fmoc-allyl-Asp(OtBu) are reported 
in the experimental part. The peptides are synthesized in solid phase using the 
Fmoc methodology and subsequently purified by preparative HPLC (see 
Experiment part). 
In a specific way is explained an example of in-depth analysis that it was 
performed for each samples. Pentapeptide Ala-Gly-Gly-Phe-Cys-NH2 (compound 
26) has been studied as an individual and as conjugated to ally-glucose in batch 
and in flow. 
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13C-DEPT AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
COSY AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC AGGFC (26) 
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HMQC AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The two-dimensional NMR analysis allowed the identification of the exact chemical 
shifts of all protons and carbons of the peptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: 
1
H and 
13
C chemical-shift of the peptide 26. 
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To understand better the reaction product and byproduct are shown the 1H NMR 
spectrum of the allyl-glucose. 
 
 
 
 
 
 
 
 
 
 
Figure 30: 
1
H NMR spectra of allyl-glucose. 
 
This spectra puts in evidence the 1H chemical shifts of the two protons involved in 
the olefinic bond characteristic of allyl-sugar at 5.35 ppm and 5.26 ppm. 
 
Below there are displayed the 1H NMR spectra of the reaction products. 
 
 
 
 
Figure 31: Left 
1
H NMR spectra of Thiol-ene product, right 
1
H NMR spectra of sulfoxide byproduct. 
 
The left spectrum demonstrates that the reaction took place with good result and it 
is visible the disappearance of the signals of the two olefinic protons (5.26 ppm-
5.35 ppm shown in the 1H spectra of allyl-glucose) with the appearance at 2.8 ppm 
of the signal indicative of the formation of thio-ether bond. The right spectrum 
exhibits the secondary product which is the corresponding sulfoxide. As proof of 
the two products there are also the exact masses (see experimental part). 
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Subsequently it was synthesized an other series of simple Pentapeptide model by 
inserting in position 3 and 4 aminoacids acidic, and neutral hydrophilic with in side 
chain amide or alcohol function in order to observe, possibly, which other 
conditions prevent the success of Thiol-ene reaction. In the scheme below there is 
the peptides sequence studied. 
 
Scheme 3: List of Pentapeptides of the second series. 
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In this series for convenience of analysis has been introduced a Phe in position 1 
as a chromophore that it has allowed a better purification. 
All Pentapeptides were reacted with the allyl-glucose and like the previous ones 
were subjected to spectroscopic analysis. Here it reports the complete analysis 
carried out on the compound 34 for example (Phe-Gly-Thr-Gly-Cys-NH2). 
1H FGTGC (34) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
13C-DEPT FGTGC (34) 
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COSY FGTGC (34) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC FGTGC (34) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC FGTGC (34) 
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The two-dimensional analysis allowed to assign the various chemical shift of all 
the protons and carbons of the sequence. 
 
Figure 32: 
1
H and 
13
C chemical-shift of the peptide 34. 
 
The NMR analysis of the reaction products has not been made because the exact 
mass spectrum confirmed the good outcome of the reaction. 
HRMS THIOL-ENE COMPOUND (50) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All peptides tested work successfully in Thiol-ene reaction. No difference it was 
observed in the reaction play in flow or in batch. 
Following the good results obtained with the pentapeptide and the ally-sugar, the 
last reaction that it has been done was the ([Cys]18 N/OFQ (1-17)-NH2) with the 
same allyl substrate. In this latter case, the Thiol-ene reaction was successfully 
and, as showed by HRMS it has been obtained both the thiol ether product and 
the corresponding sulfoxide.  
The reaction condition was the same applied to all peptides seen before (it 
explained in experimental section). 
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COMPOUND (60) 
 
 
COMPOUND (60bis) 
 
 
Figure 33: Structures of compound 60 and 60bis. 
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HRMS THIOL-ENE COMPOUND (60-60bis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using the substrate like NOP pharmacophore with certain cluttered due to the 
presence of 18 aminoacids in the chain, the reaction of Thiol-ene has given 
positive results. 
 
 
 
 
 
 
 
 
 
 
[M+3H]
3+
 
[M+4H]
4+
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4. CONCLUSION 
 
In this work it was investigated the possibility to synthesize bivalent molecules able 
to activate the NOP and MOP opioid receptors. Molecules with this 
pharmacological profile may represent a new class of analgesic drugs with fewer 
side effects compared to classical opioids currently used in the treatment of pain. 
The molecules investigated have a peptide structure for which the way suitable to 
administer should be intrathecally. It was studied the biological activity of MOP 
series of new pharmacophores drawn on the structure of MOP endogenous 
ligands and functionalized in the C-terminal portion with an appropriate way to be 
used in the synthesis of NOP/MOP bivalent molecules. It was planned to adopt 
two chemoselective reaction for this aim: Thio-Michael and Thiol-ene reaction. 
The Thio-Michael reaction took place in mild conditions with extreme speed and 
high efficiency, confirming previous observations obtained in the research lab 
where I did my thesis work and that they had shown the Thio-Michael reaction as 
ideal for the synthesis of molecules of bivalent peptide type. 
At the beginning was selected like MOP substrate a derivate of dermorphin H-Tyr-
DAla-Phe-Gly-Tyr-Pro-Ser-Lys(Ac)-NH2 (compound 1) to link with the NOP 
substrate [Cys18]N/OFQ-NH2 through Thiol-Michael reaction. Each 
pharmacophores has been functionalized to obtain the first bivalent ligand 
(compound 24), the activity in vitro of the MOP substrate has shown 10-fold less 
potency respect to the standard opioid ligand and 2-fold less active respect the 
natural ligand N/OFQ; furthermore it is known that in vivo the potency of 
dermorphin is 100-fold higher. For this reason it was decided to find novel MOP 
pharmacophores able to bind to the standard NOP pharmacophore and to exhibit 
in vivo a potency comparable to that of N/OFQ. Between the new MOP ligands it 
was identified the sequence H-Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Lys(Ac)-NH2 
(compound 20), which maintains a good ability to bind and activate the MOP 
receptor with a 100-fold less potency than endogenous ligand. This peptide was 
conjugated with the NOP ligand nociceptin exploiting the reaction of Thio-Michael 
like the bivalent ligand previously described. The bivalent ligand achieved, 
compound 25, is able to bind the MOP receptor with a potency 100-fold lower than 
the standard dermorphin ligand. Compound 25 activates the NOP receptor with a 
potency only 3-fold lower than the physiological ligand N/OFQ.  
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Afterwards compound 24 and 25 will be tested in vitro on tissues expressing the 
native NOP and MOP opioid receptors to assign the NOP and MOP potency. 
Otherwise, Thiol-ene reaction is not been satisfying to produce a NOP/MOP 
bivalent ligand. 
The first MOP substrate (compound 1), adequately functionalized in C-terminal 
portion with an olefinic group, is been reacted with the NOP substrate [Cys18] 
N/OFQ-NH2 giving a failure data. In literature thiol-ene reaction is known as a 
good chemoselective and regioselective procedure for non peptide chemistry. In 
our hands, with functionalized peptide, this reaction showed some limitation; in 
order to better understand the chemical pathway involved in peptide thiol-ene 
chemistry it was planned an initial methodological study. 
To reach the scope it has been chosen a pentapeptide prototype in order to deeply 
analyse its NMR features. 
Every peptide is functionalized in C-terminal with a Cys, making available the thiol 
function involved in Thiol-ene reaction. As alkene substrate it was used an olefin, 
the substrate mainly elected was the allyl-glucose. In each prototype is been 
introduced a different aminoacid with side chains variable to assess whether some 
of these are involved in side reactions sequence dependent. The peptides were 
analyzed by NMR in order to assess any changes of the chemical shift in the case 
of no successfully of reaction. The introduction of aromatic aminoacids 
characterized by bulky side chains such as tryptophan, phenylalanine, tyrosine 
and histidine did not result alterations in the achievement of the reaction. 
Similarly the introduction of hydrophilic aminoacids like threonine with an alcohol 
function in side chain, glutamine and asparagine with an amide function with 
variable length in side chains, do not change the Thiol-ene reaction. 
Finally the introduction of aminoacid acid as aspartic and glutammic acid, 
identified from a carboxylic acid side chain of different length, do not modify the 
good success of the reaction. All reactions tested have given the product of Thiol-
ene and its byproduct sulfoxide. 
The same reaction was performed using the allyl-glucose substrate added to bulky 
substrate NOP [Cys18] N/OFQ-NH2 and the reaction is gone successfully, 
generating the unexpected sulfoxide byproduct. In conclusion, it can say that the 
optimization of the reaction time and the maintainance of inert environment are 
necessary requirements to provide mainly the desired product. 
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1. INTRODUCTION 
 
1.1 G-quadruplex DNA 
It is important to remember that the metabolically active form of DNA in its major 
activities like replication, transcription, repair and recombination is single-stranded; 
while the double helix is actually its inactive form33. 
For DNA to become single-stranded it must overcome thermodynamic and kinetic 
barriers necessary for the dissociation of the double helix.  Commonly, this could 
be achieved in the cell with small molecules or binding proteins that recognise 
single-stranded DNA (such as chaperone proteins). Polypurine–polypyrimidine 
and other repetitive sequences can form non duplex and/or higher-ordered 
chromatin structures easily, which relate to a wide variety of biological activities. 
One family of structures originating from guanosine-rich tracts is referred to as G-
quadruplex or G-tetraplex (Figure 1), first reported by Davies et al. in 196239 34.  
 
 
 
 
 
 
 
 
 
Figure 1: G-quadruplex structure. 
 
A G-quadruplex is a single-stranded DNA secondary structure that consists of 
multiple vertically stacked guanine tetrads. It is characterized from Hoogsteen 
hydrogen bonds between the four guanines to form a planar G-tetrad35. 
 
 
 
 
 
                                                        
33
 N. W. Luedtke, Chimia, (2009), 63, 134-139. 
34
 M. Gellert, M. N. Lipsett, D. R. Davies, Proc. Natl. Acad. Sci USA, (1962), 48, 2013-2018). 
35
 Y. Qin, L. H. Hurley, Biochimie, (2008), 90, 1149-1171. 
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This DNA complex has different features, but common elements include: 
 Four DNA strands formed from one or more DNA sequences; 
 The presence of many overlays of stacked G-quartets, linked by 
phosphodiester backbone; 
 The existence of non-G nucleotides as T and A can form non-helical loop 
regions; 
 DNA complex can assume a parallel or anti-parallel structure or a mixture of 
both; 
 For the stability of the complex is required the presence of cations like Na+ 
and K+. 
G-quadruplexes exhibit a remarkable dependency on alkali cations for their 
formation and stabilization.  It has been reported that Na+ induces an anti-parallel 
strand; while K+ causes a completely different parallel structure36.  
Finally the ions in the solution and the crowding in the environment influence the 
conformation of the complex. 
 
 
 
 
 
 
 
Figure 2: Loop region in G-quadruplex structures. 
 
DNA complex can form intermolecular G-quadruplex structures as intermediates 
or precursors of recombination and/or viral integration, while intramolecular G-
quadruplex has been implicated in the regulation of gene expression and 
chromosome stability39. 
 
 
 
 
 
                                                        
36
 J. Cuesta, M. A. Read, S. Neidle, Mini Rev. Med. Chem., (2003), 3, 11-19. 
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Figure 3: Structure of G-tetrad and an example of inter- and intramolecular G-quadruplex. 
 
It is known that the variable polymorphism of DNA complex can adopt another 
structure called i-motif. The guanine tracts of a G-rich strand can form G-
quadruplex structures, which are independent of pH and readily form at 
physiological pH; while cytosine tracts form the i-motif structures, that require 
hemiprotonated cytosine-cytosine pairs and they are dependant of pH. To provide 
an i-motif an acidic environment is often required37. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: G-C base pair in G-quadruplex and C-C
+ 
base pairs in i-motif complex. 
 
Approximately 30-40% human promoters contain a G-quadruplex motif and they 
are known to regulate many human genes (retinoblastoma susceptibility, insulin, 
muscle-specific, vascular endothelial growth factor, hypoxia inducible factor 1a, 
fragile X mental retardation genes), including oncogenes (c-myc, Bcl-2, c-kit, 
VEGF)38.  
The important interest in this particular complex grew for its relevant biological role 
to “turn on” and “turn off” some physiological events39.  
 
                                                        
37
 S. Dhakal, J. Schonhoft, D. Koirala, Z. Yu, S. Basu, H. Mao, J. Am. Chem. Soc., (2010), 132, 8991-8997. 
38
 D. Monchaud, M.-P. Teulade-Fichou, Org. Biomol. Chem., 6, (2008), 627-636. 
39
 T.-M. Ou, Y.-J. Lu, J.-H. Tan, Z.-S. Huang, K.-Y. Wong, L.-Q. Gu, ChemMedChem, (2008), 3, 690-713). 
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1.2 Important G-quadruplexes in the human genome 
A relevant number of important regions in the humane genome adopt G4 
structures such as regulatory sequences, switch region, telomeric ends and 
oncogene promoters. 
 
Telomeres 
Telomeres are non-coding DNAs consisting of tandem repeats of the sequence 
d(TTAGGG), located at the end of linear chromosomes and they are a safety 
system within each chromosome arm. 
The control of telomere length is very important for cell cycle control, cellular 
immortalization and tumorogenesis. For this reasons the folding and the 
stabilization of a variety of G-quadruplexes in G-rich at the ends of telomeres 
sequences induce a normal regulation of their activities of in the cell cycle and 
other events45.  
 
 
 
 
 
 
 
 
Figure 5: Scheme of the stabilization through a specific ligand of G4 and the switch off of telomerase activity. 
 
Bcl-2 
The human Bcl-2 gene contains a G-rich tract upstream of the P1 promoter, which 
is critical for the regulation of Bcl-2 expression. It is a proto-oncogene and with 
other proteins it is involved in the control of programmed cell death. In different 
cancers it has been shown to be overexpressed. 
The control of these G-rich sequences allows a crucial step in the regulation of 
Bcl-2 transcription45. 
 
VEGF 
VEGF is human vascular endothelial growth factor with a G-rich sequence that 
controls its expression. It is a pluripotent cytochine and angiogenic growth factor, 
and it is involved in the stimulation of the proliferation, migration, survival and 
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permeability of endothelial cell. This factor, in many tumor processes, has a high 
activity, because during the cancer disease mechanism there is an elevated 
production of new blood vessels that require nutrients and oxygen. The regulation 
of this factor could be a fundamental point to slow this uncontrolled growth45. 
 
c-kit 
c-kit is a proto-oncogene and belongs of the family of growth factor receptors. It 
contains G-rich tracts in the site essential for the promoter activity, which have 
high conservation in primates. 
It has a crucial role in the regulation of the stimulus of proliferation, differentiation, 
migration and survival signal cell system45. 
 
c-Myc 
c-Myc is an oncogene , which has a putative G-quadruplex-forming sequence in 
the promoter region of the gene40. 
Simonsson et al. proposed the first intramolecular G-quadruplex structure within 
the c-Myc NHE III1 region, which was described as an antiparallel-stranded 
structure involving three G-tetrads formed from four G-tracts linked by two lateral 
loops and a central diagonal loop. c-Myc is linked to a wide range of human 
cancers, it modulates 10-15% of all cellular genes involved in cell cycle regulation, 
apoptosis, metabolism, cellular differentiation and cell adhesion. Its 
overexpression is linked with many malignant tumors, the stabilization of G4 in this 
region can suppress c-Myc transcriptional activation, down-regulate the 
expression of it, inhibit cell proliferation and induce apoptosis of cells45 41. 
 
 
 
 
 
 
 
 
 
                                                        
40
 H. T. Le, M. C. Miller, R. Buscaglia, W. L. Dean, P. A. Holt, J. B. Chaires, J. O. Trent, Org. Biomol. Chem., (2012), 10, 
9393-9404. 
41
 V. Gonz´alez, L. H. Hurley, Annu. Rev. Pharmacol. Toxicol., (2010), 50, 111-129. 
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Figure 6: Scheme of the structure and biological role of c-Myc. 
 
ILPR: insulin linked polymorphic region 
The insulin-linked polymorphic region is non coding minisatellite in the human 
insulin gene promoter. It is located 363 base pairs upstream of the insulin gene, 
known like a genetic loci involved in the genetic dysfunction associated with 
insulin-dependent diabetes mellitus42. It is composed of tandem repeats of the 
consensus sequence 5’-ACAG4T(G/C)(T/C)G4-3’
43 . The polymorphism of this 
region comes from a different repeat number of the oligonucleotides and as such 
the ILPRs are divided into three classes in relation to their length: class 1 (up to 
700bp), class 2 (up to1600bp) and class 3 (up to 2500bp)44. Variants of the ILPR 
sequence, that destabilize or preclude G-quadruplex formation, are also related 
with lower transcription rates, suggesting a possible role of G-quadruplex 
formation in the regulation of transcription the insulin gene. Supporting information 
was observed in the transcription factor Pur-1, which preferentially binds to ILPR 
tandem repeats that form inter- or intramolecular G-quadruplex structures. This 
has suggested the hypothesis that Pur-1 regulates insulin transcription through 
recognition of G-quadruplex structures in the ILPR; however, seems that 
regulation insulin gene transcription depending on an interplay of mutiple protein 
factors binding.  
The G-quadruplex recognition did not in all cases correlate with transcriptional 
activity, suggesting that there may be different regulatory mechanisms that involve 
other protein interactions with the transcription mechanism or modifications of the 
ILPR complex48. The involvement of ILPR G-quadruplex in insulin gene 
expression suggests the possibility that a stabilization of this complex could 
restore the correct expression of the INS gene in diseases such as diabetes. 
                                                        
42
 A. C. Connor, K. A. Frederick, E. J. Morgan, L. B. McGown, J. Am. Chem. Soc., (2006), 128, 4986-4991. 
43
 M. C. U. Hammond-Kosack, K. Docherty, FEBS Letters, (1992), 301, 79-82. 
44
 M. C. U. Hammond-Kosack, B. Dobrinski, R. Lurz, K. Docherty, M. W. Kilpatrick, Nucleic Acids Research, (1992), 20, 231 
-236. 
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Figure 7: G-tetrad and schematic representation of ILPR upstream of insulin gene. 
 
1.3 Small molecules binding to G-quadruplexes structures 
The prevalence of these G-quadruplexes and their importance in biological 
processes has led to the study and development of small molecule ligands of the 
complex. The stabilization of the tetraplex can successfully restore some biological 
events involved in fundamental physiological mechanisms. 
There are several ways to classify the different ligands44. 
 
Protonated G-quadruplex ligands 
Neidle, Hurley et al. suggest the development of compounds that are conceived 
with large flat aromatic systems prone to -stacking with a G-tetrad platform, while 
retaining reasonable water solubility. The molecule has to show both hydrophobic 
and hydrophilic characteristics. An usual way to ensure this duality is to introduce 
protonable side arms like amine groups around an aromatic core; the potential 
ligand become watersoluble, with the charge far from the hydrophobic centre45.  
The best compound produced was BRACO-19 able to interact simultaneously with 
three G-quadruplex grooves thanks to three side arms. Subsequently 
investigations have recently demonstrated the efficiency of BRACO-19, but it has 
been somewhat limited by pharmacological parameters (such as cellular uptake or 
membrane permeability44. 
 
 
 
 
                                                        
45
 D. Sun, B. Thompson, B. E. Cathers, M. Salazar, S. M. Kerwin, J. O. Trent, T. C. Jenkins, S. Neidle, L. H. Hurley, J. Med. 
Chem., (1997), 40, 2113-2116. 
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BRACO-19 
 
Anionic G-quadruplex ligands 
Molecules belonging to this category are less known because the protonable side 
chains play a relevant role in the interaction with the complex. 
A recent study of Sugimoto et al. suggests that the cationic molecules have high 
affinity but insufficient selectivity to G-quadruplexes compared with double-
stranded DNA (dsDNA). Cu-APC (anionic copper phthalocyanine) is an anionic G-
quadruplex-ligand and it should not engage in electrostatic interactions with G-
quadruplex because of their negative charges; however, it should engage in – 
stacking interactions with G-quadruplex. The binding affinity is apparently 
sacrificed for selectivity. Consequently, large -planar compounds with anionic 
groups can be new scaffolds to develop G-quadruplex ligands46.  
 
 
 
 
 
                                        
Cu-APC 
 
Metallo-organic G-quadruplex ligands 
This class of molecules is highly interesting thanks to their easy synthetic access 
and their very promising G-quadruplex ligand properties. The central metal 
assumes the same position of the cation channel of G-quadruplex, enhancing the 
stacking interactions of the chelating agent inside 47 . Their cationic or highly 
polarized nature is also a clear advantage to improve the association with the 
negatively charged G-quadruplex-DNA. 
The metal centre is a parameter that plays an important role in the selectivity. 
An example of metallo-organic ligand is Cu TMPyP4. 
                                                        
46
 H. Yaku, T. Murashima, D. Miyoshi, N. Sugimoto, Chem. Commun., (2010), 46, 5740-5742. 
47
 J. E. Reed, A. A. Arnal, S. Neidle, R. Vilar, J. Am. Chem. Soc., (2006), 128, 5992-5993. 
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Cu TMPyP4 
 
Neutral macrocyclic G-quadruplex ligands 
This class of ligands is small, with Telomestatin belonging to this category. Its one 
of lead compound used to recognize the G-quadruplex. The interest for 
Telomestatin is grown for its selectivity toward DNA single strand and for its 
neutral and cyclic shape. The peculiarity of this macrocyclic is that it works very 
well as a telomerase inhibitor, stabilize G-quadruplex without the presence of a 
cation salt, contain the proliferation of telomerase positive cells through the 
change of the length and conformation of telomeres, and finally induces the 
dissociation of telomere-related protein from telomeres. Other macrocyclic 
molecules were synthetized with the same core characterized from a tetra- or 
hexa-oxazole with different substitutions to mimic Telomestatin activity48 44. 
 
 
 
 
 
 
 
 
Telomestatin 
 
 
 
 
 
 
N-Methylated aromatic G-quadruplex ligands 
                                                        
48
 G. S. Minhas, D. S. Pilch, J. E. Kerrigan, E. J. LaVoie, J. E. Rice, Bioorg. Med. Chem. Lett., (2006), 16, 3891–3895. 
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The design of the molecules of this category is based on the introduction of N-
methylated aza-aromatic moieties. 
This allows for a reduction of the electron density of the aromatic portion, an 
increasing of the -stacking ability of the ligand and an improvement of the water 
solubility without the presence of cationic functionalities in side-chains. An 
example reported from Hurley et al.49 explains that TMPyP4 belongs to this class 
and it has exclusive characteristics: good affinity for G-quadruplex, the ability to 
inhibit telomerase50, down-regulate the oncogenes expression and convert the 
antiparallel system in to a parallel structure of the G-complex. It works with an 
intercalation between adjacent G-tetrads and stacking of the porphyrin onto the 
external G-quartet without direct contact with the DNA-complex 44 45. 
 
 
 
 
 
 
 
TMPyP4 
                                                        
49
 K. Guo, A. Pourpak, K. Beetz-Rogers, V. Gokhale, D. Sun, L. H. Hurley, J. Am. Chem. Soc., (2007), 129, 10220-10228. 
50
 R. T. Wheelhouse, D. Sun, H. Han, F. X. Han, L. H. Hurley, J. Am. Chem. Soc., (1998), 120, 3261-3262. 
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2. AIM OF THE PROJECT 
 
The insulin-linked polymorphic region (ILPR) is a regulatory sequence located 363 
base pairs (bp) upstream of the human insulin gene. It is characterized by multiple 
repeats of consensus sequence rich in guanine residues.  The ILPR sequence is 
5’-ACAG4T(G/C)(T/C)G4-3’. This kind of sequence assumes a particular structure 
defined as a G-quadruplex (G4) or tetraplex, characterized from only oligomers 
containing one or several runs of guanine residues. 
These kind of structures are stabilized by Hoogsteen hydrogen bonding, involving 
the N-7 positions of the constitutive G-tracts49. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic representation of ILPR upstream of the INS gene. 
 
The ILPR is able to allow the activation and the expression of insulin gene, 
probably not directly inducing the expression of the gene, but through a relevant 
role in the midst of mechanisms of different binding proteins that participate in the 
activation of the gene itself48.  
In the literature there is some evidence consistent with in vivo formation of G- 
quadruplexes, which have been proposed to increase the expression of insulin51.  
Since insulin is directly related to the pathogenesis of diabetes, the potential 
regulatory role of the G quadruplex in the insulin expression has received close 
attention. 
Some cations and small molecules stabilize this DNA complex. These types of 
molecules are able to intercalate in this structure and create different 
interactions45. 
 
                                                        
51
 G. Catignani Kennedy,
 
M. S. German, W. J. Rutter, Nature Genetics, (1995), 9, 293-298. 
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Figure 9: A representation of the possible interaction of a ligand with G4. 
 
The main project aim is to alter the functionality of the ILPR, and subsequently 
alter INS gene expression using small molecules as ligands that will bind to and 
regulate the ILPR. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Structure of the docking model from a G4 and an interaction of a small molecule like TMPyP4. 
 
This project was developed in some different steps. 
 
First step: it was analyzed the concentration appropriate of oligonucleotides to 
proceed with the EMSA assay. It was used a library of oligonucleotides and then 
selected the best for these needs. (see table 1 experimental part). 
 
Second step: initial focus on molecules known in literature to have a good ability to 
stabilize the tetraplex 52 . They are commercially available chemicals, such as 
porphyrins, in particular TMPyP4 (one of lead compound) and two molecules 
derived from this, Mesoporphyrin IX Dihydrochloride and Protoporphyrin IX42. 
                                                        
52
 D.-F. Shi, R. T. Wheelhouse, D. Sun, L. H. Hurley, J. Med. Chem., (2001), 44, 4509-4523. 
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Third step: it is planned a synthesis of a new compound triazine derivate to 
enhance the binding and stabilize the G-quadruplex. 
 
In order to show the changing of conformation of ILPR, it is examined other 
oligonucleotides such as c-Myc (Pu27) and Bcl-2 as sequences known capable of 
forming G-quadruplex. 
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3. DISCUSSION  
 
3.1 EMSA system approach and evaluation of different oligonucleotides 
 
We tried to use different concentrations of oligonucleotides to know the best 
concentration to be analyzed by EMSA. Every oligos are involved in the gene 
expression. 
 
Tel.(1xG4)                     
[Btn]TTAGGGTTAAGGGTTAGGGTT
AGGG 
Tel.(2xG4)                    
[Btn]TTAGGGTTAAGGGTTAGGGTTAGGGTTAGGGTTAAGGGTTAGG
GTTAGGG 
ILPR-1(1xG4)                
[Btn]ACAGGGGTGTGGGGACAGG
GGTGTGGGG 
ILPR-1(2xG4)                
[Btn]ACAGGGGTGTGGGGACAGGGGTGTGGGGACAGGGGTGTGGG
GACAGGGGTGTGGGG  
Bcl-2                              
[Btn]GGGCGCGGGAGGAAGGGGG
CGG 
c-Myc(Pu27)                
[Btn]TGGGGAGGGTGGGGAGGGTGGGGAAGG 
VEGF                             
[Btn]GGGCGGGCCGGGGGCGGG 
c-Kit21                           
[Btn]GGGCGGGCGCGAGGGAGGG 
ILPR-2                             
[Btn]ACAGGGGTCTGGGGACAGGG
GTCTGGGG 
ILPR-3                             
[Btn]AGAGGGGTCTGGGGAGAGGGGTCTGGGG 
ILPR-4                            
[Btn]ATAGGGGTGTGTGGATAGGG
GTGTGTGG 
 
 
Table 1: The above table shows all oligos used in the gel-based assays, with sequences being shown in a 5’ 
to 3’ orientation.  [Btn], biotin label covalently linked to 5’ end of each oligo 
 
Oligos use in this study (Table 1) undergo a process of denaturation by heating to 
95°C for 5 minutes; followed by a gradual decrease (-1°C/minute) in temperature 
down to 4°C. As a control oligos were also heated to 95°C only with no slow 
cooling. 
Preliminary experiments shown in figure a, b, c, d of each oligos lead to an oligo 
concentration of 10 nM being chosen for the experiements that follow. 
Oligos were tested at different concentrations: 10 µM, 100 nM, 50 nM, 10 nM and 
1 nM. In a preliminary screening of all oligos, conformational changes in the 
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presence or absence of KCl were tested.  Previous studies by Simonsson et al. 
have demonstrated that under physiological conditions, the guanine-rich 
sequences can create a G-quadruplex structure and that is K+-dependent41. 
                                                          C-Myc(Pu27), VEGF, c-Kit21, Bcl-2 
 
  
 
 
 
 
Figure 11: The EMSA intramolecular G-quadruplex structures of C-Myc(Pu27), VEGF, c-Kit21, Bcl-2 
promoter in the presence (+) or absence of 100 mM KCl. 
 
 
All oligos tested showed a large increase in the amount of secondary structure 
formation in the presence of K+ (Figure 11). KCl concentrations of 100 mM are at 
physiological concentrations of K+ found in most human cells. 
 
3.2 Investigation of interaction between G-quadruplexes and small-
molecules ligands 
 
Four oligos were selected to be tested further:  
ILPR-1(1xG4); ILPR-1(2xG4); c-Myc(Pu27) and Bcl-2.  ILPR oligos are either one 
or two repeats of the ILPR G-quadruplex sequence with 1 or 2 repeats of 5’-
ACAGGGGTGTGGGGACAGGGGTGT-3’ DNA sequence.  c-Myc(Pu27) and Bcl-2 
oligos were used as controls because they are examples of well characterised and 
studied G-quadruplexes. 
 
TMPyP4 (5,10,15,20Tetrakis(1methylpyridinium4yl)porphyrintetra(p-
toluenesulfonate) is a cationic porphyrin which is known to inhibit the telomerase in 
both a cell-free system and living cells and to downregulate the expression of 
oncogenes, such as c-Myc, and to convert anti-parallel topologies to parallel forms 
of quadruplexes44. 
 
 
 
 
 
 
(+)          (+)          (+)          (+)           
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Figure 12(a,b,c,d): Bar graph showing the gel-based assay results of the effect of TMPyP4 on formation of 
secondary structure.  Bars represent the average of five experiments quantified using Image J software. The 
samples were heated to 95°C then cooled slowly as explained on page 162. Heated sample, control; 0, 100 
mM KCl; 1, 1μM TMPyP4; 2,5, 2,5μM TMPyP4; 5, 5μM TMPyP4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: x y scattergraph that summarizes the data shown in the bar graphs in figures 12(a,b,c,d). 
 
In literature, there are some evidence that the best concentrations of Porphyrins in 
the sample are in range between [1μM] ≥ [5μM]53. 
                                                        
53
 M. A. Shammas, R. J. S. Reis, M. Akiyama, H. Koley, D. Chauhan, T. Hideshima, R.K. Goyal, L. H. Hurley, K. C. 
Anderson, N. C. Munshi, Mol. Cancer. Ther., (2003), 2, 825-833. 
a.TMPyP4/ILPR-1(1xG4) b.TMPyP4/ILPR-1(2xG4) 
c.TMPyP4/c-Myc(Pu27) d.TMPyP4/Bcl-2 
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Indeed sumarizing the data (Figure 12), it is clear TMPyP4 [5μM] can induce the 
formation of secondary structure with ILPR-1(1xG4), while ILPR-1(2xG4) produces 
less secondary structure in the presence of TMPyP4.  One possible explaination of 
this effect could be the weight and the length of the ILPR-1(2xG4) structure that 
reduce the intra- and intermolecular interaction of the ligand. In x y scattergraph 
(Figure 13) the R2 is a value of the linear regression that puts in linear relationship 
a dependent variable (the average effect) with an independent value (substance 
concentration). In figure 13 ILPR-1(1xG4) (R2 = 0.8155) and Bcl-2 (R2 = 0.8329) 
demonstrate a good fit with the regression line; while ILPR-1 (2xG4) and c-Myc 
(Pu27) gave results that did not fit well to the linear regression line for these data. 
 
The second ligand tested was Mesoporphyrin IX Dihydrochloride, a different kind 
of porphyrin for its different functionality in the external chains, the aromatic 
system is substituted with alifatic chains. Previous research has identified this 
compound as a potential quadruplex ligand54.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
54
 J. M. Nicoludis, S. P. Barrett, J.-L. Mergny, L. A. Yatsunyk, Nucleic Acids Research, (2012), 40, 5432-5447. 
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Figure 14(a,b,c,d): Bar graph showing the gel-based assay results of the effect of Mesoporphyrin IX 
Dihydrochloride on formation of secondary structure.  Bars represent the average of five experiments 
quantified using Image J software. The samples were heated to 95°C then cooled slowly as explained on 
page 162. Heated sample, control; 0, 100 mM KCl; 1, 1μM Mesoporphyrin IX Dihydrochloride; 2,5, 2,5μM 
Mesoporphyrin IX Dihydrochloride; 5, 5μM Mesoporphyrin IX Dihydrochloride. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: x y scattergraph that collects the data displayed in the bar graphs in figures 14(a,b,c,d). 
 
Mesoporphyrin IX dihydrochloride was incubated with different oligos. 
Each data set (Figure 14) showed Mesoporphyrin IX dihydrochloride had a good 
activity at [2.5μM], that is not significantly able to stabilize the G-quadruplex but it 
can change the quadruplex conformation. In the x y scattergraph R2 indicates that 
a.Mesoporphyrin IX 
Dihydrochloride/ILPR-1(1xG4) 
b.Mesoporphyrin IX 
Dihydrochloride/ILPR-1(2xG4) 
c.Mesoporphyrin IX 
Dihydrochloride/c-Myc(Pu27) 
d.Mesoporphyrin IX 
Dihydrochloride/Bcl-2 
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only the Bcl-2 oligo shows a strong correlation with the linear regression line (R2= 
0.99896). 
 
The third ligand analized was Protoporphyrin IX, which has similar lateral chains of 
Mesoporphyrin with more conjugations of alkene chains. In the literature it has 
been shown to interact with different DNA structures55.  
 
Figure 16(a,b,c,d): Bar graph showing the gel-based assay results of the effect of Protorphyrin IX on 
formation of secondary structure.  Bars represent the average of five experiments quantified using Image J 
software. The samples were heated to 95°C then cooled slowly as explained on page 162. Heated sample, 
control; 0, 100 mM KCl; 1, 1μM Protorphyrin IX; 2,5, 2,5μM Protorphyrin IX; 5, 5μM Protorphyrin IX. 
 
 
 
 
 
 
 
 
                                                        
55
 T. Li, E. Wang, S. Dong, Anal. Chem, (2010), 82, 7576-7580. 
a.Protoporphyrin IX/
ILPR-1(1xG4) 
b.Protoporphyrin IX/
ILPR-1(2xG4) 
c.Protoporphyrin IX/c-
Myc(Pu27) 
d.Protoporphyrin IX/Bcl-2 
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Figure 17: x y scattergraph that gathers the data seen above in the bar graphs in figures 16(a,b,c,d). 
 
In the bar graph (Figure 16) we can observe that ILPR-1(1xG4) with 
Protoporphyrin has a large change of conformation, at [2.5 M] and [5M]. These 
data are not backed up by the x y scattergraph (Figure 17) because the R2 value is 
better for Bcl-2 (R2= 0,99195) and ILPR-1(2xG4) (R² = 0,97756). 
Every oligonucleotide have a different behaviour in the presence of 
Protoporphyrin. 
 
Taking a general comparison between the three porphyrins studied we can 
observe that TMPyP4 is able to induce change in DNA conformation, while 
Mesopoprhyrin having an intermediate activity and Protoporphyrin is the least 
effective. 
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3.3 Rational synthesis of the new compound 
The quadruplex-stabilization happens via  stacking and electrostatic inter- 
actions due to the binding of the ligand (usually a flat aromatic molecule) on the G-
quartet usually on the top and/or bottom of the external- face of the quadruplex42. 
Electrostatic interactions are required between charged ligands and the G-
quadruplex DNA scaffold, they induce an important selectivity, but also pinpoint 
the role of protonated sidearms for strongly partecipation in the stabilization. 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Interactions between G-quartet and ligand with protonated sidearms. 
 
Synthetizing a compound with similar characteristics required to bind with DNA 
structures like the aromatic core, basic functionality like pyridine and an 
hydrophobic portion, was designed. In the literature there are different types of G-
quadruplex ligand39 44. 
 
 
The synthesis of the new compound has been designed with the idea of using a 
strategy of synthesis well known: the "Click chemistry", in particular exploiting the 
advantages of Cu(I)-catalyzed Huisgen cycloaddition reaction56. 
 
 
 
 
 
                                                        
56
 A. D. Moorhouse, A. M. Santos, M. Gunaratnam, M. Moore, S. Neidle, J. E. Moses, J. Am. Chem. Soc., (2006), 128, 
15972-15973. 
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Scheme 1: Scheme of synthesis. 
 
From tBu-aniline it was did a iodination (compound 2) and a deamination to obtain 
the compound 4-(tert-butyl)-2,6-diiodoaniline each in a quantitative yield 
(compound 3)57.  
Then it is introduced an alkinic function through a Sonogashira reaction to achieve 
((3-(tert-butyl)-5-iodophenyl)ethynyl)trimethylsilane (compound 4) in a middle yield. 
The release of the protecting group has allowed to yield the desired alkyne 
compound 5. 
In the same time from the compound 3 it was synthetized its diazide (compound 
6). Subsequently the reaction between the compound 1,3-diazido-5-(tert-
butyl)benzene (compound 6) and 1-(tert-butyl)-3-ethynyl-5-iodobenzene 
                                                        
57
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(compound 5) has produced the 1,1'-(5-(tert-butyl)-1,3-phenylene)bis(4-(3-(tert-
butyl)-5-iodophenyl)-1H-1,2,3-triazole) in a good yield (compound 7)58. 
In order to get the compound ZAL026 (compound 8) it was used a Stille reaction, 
in which it was done a bi-substitution of the iodine with a 2-methoxy-6-
(tributylstannyl)pyridine. 
For observe the activity of this compound was tested with the selected oligos with 
the same procedure in the EMSA assay. 
 
 
Figure 19(a,b,c,d): Bar graph showing the gel-based assay results of the effect of ZAL026 on formation of 
secondary structure.  Bars represent the average of five experiments quantified using Image J software. The 
samples were heated to 95°C then cooled slowly as explained on page 162. Heated sample, control; 0, 100 
mM KCl; 1, 1μM ZAL026; 2,5, 2,5μM ZAL026; 5, 5μM ZAL026. 
 
 
 
 
 
 
 
 
                                                        
58
  Y. Li, A. H. Flood, Angew. Chem., (2008), 120, 2689-2692. 
a.ZAL026/ILPR-1(1xG4) b.ZAL026/ILPR-1(2xG4) 
c.ZAL026/c-Myc(Pu27) d.ZAL026/Bcl-2 
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Figure 20: x y scattergraph that puts togheter the informations  collected in the bar graphs in figure 
19(a,b,c,d). 
 
The compound ZAL026 shows a slight activity with the DNA complex, but the data 
obtained with x y scattergraph indicate that the R2 values are not indicative of a 
string correlation (e.g. ILPR-1(2xG4) R2=0,78848). 
 
3.4 Circular dichroism analysis 
 
Each sample was prepared with oligonucleotides of interest in TE buffer, plus or 
minus addition of  KCl and in different thermal conditions. 
 
ILPR-1(1xG4) 
 
 
 
 
 
Figure 21a: CD spectra of ILPR-1(1xG4).  Blue spectra, TE buffer +KCl; Red spectra, heated to 95°C; Pink 
spectra, post thermal cooling to 20°C; Green spectra, post thermal cooling to 5°C. 
 
 
 
 
 
 
Figure 21b: CD spectra of ILPR-1(1xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer post 
thermal incubation and cooling to 20 °C.  
 
Aberdeen’s project  Results & Discussions 
 73 
In figure 21a and 21b the spectra of ILPR-1(1xG4) without addition of chemical is 
shown. The pink and green line are similar, the blue and red line are slightly 
different. There are four identificative peaks: positive band at 210 nm, negative 
band close to 240 nm, positive band at 260 nm and 290 nm. In the figure 21b the 
green line is representative of oligo in the absence of KCl, which shows peaks are 
at the same wavelength but are lower and wider, which may be indicative of a 
mixture of different G-quadruplex structures, that are not stable. Following this 
observation the spectra is representative that ILPR-1(1xG4) forms apparently a 
propeller-type structure of G-quadruplex59. 
 
 
 
 
 
 
 
Figure 22: CD spectra of ILPR-1(1xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer +KCl+ 
TMPyP4 post thermal cooling to 20 °C.  
  
In this case the addition of TMPyP4 highlights the peaks of the red line which are 
very similar to those of the blue line of the reference spectrum. TMPyP4 therefore 
appears to show an important role in the stabilization of propeller-type structure of 
ILPR-1(1xG4). 
 
 
 
 
 
Figure 23: CD spectra of ILPR-1(1xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer +KCl+ 
Mesoporphyrin IX Dihydrochloride post thermal cooling to 20 °C.  
 
The addition of Mesoporphyrin does not change clearly the spectra, the peaks are 
the same explained above but they are less marked (pink and green line in the 
figure 21a). This chemical does not therefore define the G-quadruplex complex. 
 
 
                                                        
59
 E. M. Rezler, J Seenisamy, S. Bashyam, M.-Y. Kim, E. White, W. D. Wilson, L. H. Hurley, J. Am. Chem. Soc., (2005), 
127, 9439-9447.  
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Figure 24: CD spectra of ILPR-1(1xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer +KCl+ 
Protoporphyrin IX post thermal cooling to 20 °C.  
 
Protoporphyrin seems more able than Mesoporphyrin, to produce quadruplex 
structures, but it does not work like TMPyP4. The peaks are the same and the 
ILPR-1(1xG4) has a propeller-type structure. 
 
ILPR-1(2xG4) 
 
 
 
 
 
Figure 25: CD spectra of ILPR-1(2xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer post thermal 
cooling to 20 °C.  
 
ILPR-1(2xG4) is twice the legth of ILPR-1(1xG4). 
These datas highlight the difference between the presence or absence of KCl. 
The introduction of KCl presents a clearly peaks (line blue) at 210 nm, 260 nm and 
290 nm positive bands while at 240 nm negative band. The CD spectrum exhibits 
a maxima-minima pattern similar to the propeller-type structure of ILPR-1(2xG4). 
 
 
 
 
 
Figure 26: CD spectra of ILPR-1(2xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer +KCl+ 
TMPyP4 post thermal cooling to 20 °C.  
 
The spectrum of the sample with TMPyP4 has a much more pronounced feature 
near 260 nm in positive typical of the parallel structure of DNA quadruplex, the 
other band at 290 nm in positive confirms the stabilization of a propeller-type G- 
complex. 
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Figure 27: CD spectra of ILPR-1(2xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer +KCl+ 
Mesoporphyrin IX Dihydrochloride post thermal cooling to 20 °C.  
 
The CD spectra of DNA is very similar when no Mesoporphyrin is present in the 
solution. There is no difference between the spectra in the presence or absence of 
mesoporphyrin. 
 
 
 
 
 
Figure 28: CD spectra of ILPR-1(2xG4).  Blue spectra, TE buffer +KCl; Red spectra, TE buffer +KCl+ 
Protoporphyrin IX post thermal cooling to 20 °C.  
 
The Porphyrin IX introduction demonstrates a lack of functionality as it cannot 
enhance quadruplex DNA formation. 
Probably the binding is not enough to stabilize more the complex. 
 
The data about ZAL026 are under study in Glasgow University. 
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4. CONCLUSION 
 
This preliminary study was used to test the capacity for different small molecules 
to alter the structure of the ILPR G-quadruplex structure.  This was achieved 
through the use of electrophoretic mobility shift assays (EMSA) carried out on 
ILPR DNA oligo sequences, to show secondary structure formation.  This was 
then further validated through the use of circular dichroism (CD). 
Overall, the main aim was to alter the functionality of the ILPR, and ultimately alter 
INS gene expression using small molecules that will bind to and regulate the ILPR. 
Firstly, a series of oligos were tested for their ability to form secondary structure 
following a denaturation by heating to 95°C.  Gradual cooling of the oligo samples 
then allowed secondary structure to form. As a control oligos were also heated to 
95°C without gradual cooling. The oligos were shown to exhibit secondary 
structure formation only in the presence of K+ cations, as is well documented in the 
literature. 
For this project four oligos were selected: ILPR-1(1xG4); ILPR-1(2xG4); c-
Myc(Pu27) and Bcl-2. The ILPR-1 oligos are based on the endogenous ILPR 
sequence found in the human genome, while the last two were chosen as well 
known G-quadruplex structres found in oncogene promoters. 
Each of the above oligos were analyzed with different small molecules to 
understand if they were able to stabilize them in their secondary structure or 
G4.The molecules tested were TMPyP4, Mesoporphyrin IX Dihydrochloride and 
Protoporphirin IX. 
The above small molecules were chosen as they have shown stabilization of G-
quadruplexes in line with the data in literature.  Based on previous experiments in 
the literature, they have exhibited the best activity with a concentration of 2.5 M 
and 5 M. Furthermore, CD analyses were carried out on these samples (oligos + 
chemical compound + cation + buffer) and the data obtained confirm that TMPyP4 
is the best stabilizer of DNA complex. In every CD spectra obtained it was 
confirmed that the ILPR quadruplex assumes a propeller-type structure in the 
presence of TMPyP4. 
Subsequently, a new molecule ligand was synthesised that was shown to interact 
and stabilise the quadruplex oligos (compound ZAL026). It was designed 
maintaining the main requirements, known in literature, to achieve a good 
interaction with the complex. This molecule was only tested with EMSA assay and 
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it has shown a slight ability to interact with the G-quadruplex. Unfortunately there 
is not CD analysis because this is currently under study. 
This study was planned with the idea to build some knowledge of how these small 
molecules may interact and influence G-quadruplex structure.  Future work will be 
based around the development of a cell culture system using luciferase and/or 
other reporter genes.  This will provide a robust and physiologically relevant assay 
to test the ability of small molecules to alter gene expression. 
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Chapter 3 
Experimental Section 
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PART 1 
4.1 General Methods 
 
Aminoacids, protected amino acids, resins for solid phase peptide synthesis and 
chemicals were purchased from Bachem, Novabiochem, Iris Biotech GmbH or 
Fluka. All other reagents were from Sigma or Merck and were of the highest purity 
available. 
 
Flash chromatography was performed on Silica gel Merck 60-200 mesh. 
 
Analytical Thin Layer Chromatographies (TLC) were performed on Macherey-
Nagel poligram SIL/UV 254 of 0,25 mm plate, using detection systems such as a 
UV lamp at 254 nm and KMnO4 in aqueous solution at 2%. 
 
NMR data were recorded on VARIAN 200MHz and 400MHz. All chemical shifts () 
are expressed in parts per million and coupling costant (J) are given in Hertz. 
Abbreviations used for peak multiplicity are: s, singlet; br s, broad singlet; d, 
doublet; t, triplet; q, quadruplet; quint, quintuplet; m, multiplet.  
The molecular weights of the intermediates and final products were determined by 
a mass spectrometer electrospray ESI MICROMASS ZMD 2000. 
The exact mass was found with a HPLC-CHIP Cube ESI-Q-TOF Agilent 
6520. 
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4.2 Peptide synthesis 
The peptides of Table 3, table 4 and [Cys18] N / OFQ were synthesized in SPPS 
using the chemical strategy Fmoc/tBu60, using an automatic synthesizer Syro XP 
(Biotage Sweden). 
This synthetic method involves the synthesis of the peptide from the C-terminal 
residue linked to a solid support, through subsequently reactions of deprotection of 
α-amino acid group attached to the peptide chain, followed by acylation of the 
amino group with the carboxyl component of the next aminoacid, suitably 
activated. For the peptide analogues were used a rink amide MBHA resin (p- 
Methylbenzhydrylamine resin). It is characterized from a neutral aminoacid 
(valine) connected to a polystyrene support (copolymer of vinylbenzene linear 
bridges with 1% of divinylbenzene) and the linker (Fmoc-Rink amide). This type of 
linker allows the removal of the peptide from the resin by treatment with TFA in 
order to obtain the C-terminal end free. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Chemical formula of the resin linker rink amide MBHA. 
 
The starting point for each synthetic cycle begins with the removal of the Fmoc 
protecting group from the α-amino function using a solution of 40% piperidine in 
DMF. The α-carboxyl functionality of each single aminoacid was activated with 
DIPCDI (N,N'-Diisopropylcarbodiimide) in the presence of HOBt 
(Hydroxybenzotriazole) using a molar excess of 4x respect to the amine 
component anchored to the resin. The side chains of the aminoacids were 
protected, when necessary, with acid labile protecting groups such as Boc for Lys; 
Pmc for Arg, tBu for Tyr, Ser and Thr, Trt for Asn, Gln and Cys. At the end of the 
synthesis process, the peptide was removed from the resin and simultaneously 
deprived of the protecting groups in the side chain, through the treatment for 1.5 h 
                                                        
60
 N. L. Benoiton, Chemistry of Peptide Synthesis. Taylor & Francis, (2005), 125–154. 
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with a solution of TFA, H2O, Et3SiH (9:0.5:0.5); the exhausted resin was removed 
by filtration and then the mixture of residue solvent evaporated. 
The crude peptide was crystallized in diethyl ether and the resulting solid purified 
by preparative HPLC. In figure 35 is reported the synthesis of peptide 20.  
The other compounds were synthesized in a similar way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Scheme of synthesis of the compound 20. 
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The peptide 20 was resynthesized and in position 7 was inserted Lys (Dde) and in 
position 1 Boc-Tyr. This strategy has been used to avoid that the basic conditions, 
necessary for the reaction with hydrazine, could make a deprotection of the 
terminal amine and a secondary reaction with the maleimide derivative to give an 
unwanted product. The deprotection of the side aminoacid residue of Lys(Dde) 
was done with  a solution of 2% hydrazine in DMF with a reaction time of three 
minutes. The resin was extracted with DMF and CH2Cl2 and the process of 
deprotection was repeated for a second time61.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Removal reaction of Lys(Dde). 
 
At this point, the NH2, in position γ of Lys, is acylated with the 4 - (2,5-dioxo- 
2,5-dihydro-pyrrol-1-yl) butyric acid according to the following stoichiometry: the 
amine component (0.05 mmol corresponding to 200 mg of resin) was suspended 
in DMF (2mL) and it was reacted with a molar excess of 4x with the 4 - (2,5-dioxo-
2 ,5-dihydro-pyrrol-1-yl) butyric acid (0.2 mmol, 40 mg), HOBt (0.2mmol, 31 mg), 
WSC (0.2 mmol, 40 mg). 
After 2 h the resin was extracted with DMF and CH2Cl2, dried and treated with the 
mixture release like for every compounds of Table 3 and [Cys18] N/OFQ-NH2 to 
give the compound 20bis (Figure 37). 
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 B. W. Bycroft, W. C. Chan, S. R. Chhabra, N. D. Hone, J. Chem. Soc. Chem. Commun., (1993), 778-779. 
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Figure 37: Compound 20bis. 
 
The compound 20bis, after purification, was condensed with the [Cys18] N/OFQ-
NH2 using the thio-Michael reaction with following stoichiometry: the compound 
20bis (0.0031 mmol, 4 mg) was reacted with a molar excess of 10% of [Cys18] 
N/OFQ-NH2 (0.0034 mmol, 8.48 mg). 
Each compound was separately dissolved in 1 ml of H2O and 1 ml of CH3CN. The 
two solutions were combined and it was added to 5% NaHCO3 (0.05 mL) to speed 
the Thio-Michael reaction (figure 38). After 5 minutes the reaction mixture was 
purified by preparative HPLC giving the desired compound 25. 
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Figure 38: Scheme of Thio-Michael synthesis for the bivalent 25. 
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4.3 Purification and analytical control 
The evaluation of the purity of the crude reaction products and final products was 
made with analytical control by HPLC using a Beckman System Gold 168 
KNAUER C-18 column (250 mm x 4.6 mm) and a UV detector with variable 
wavelength fixed at 220 nm. The mobile phase consisted in a binary eluent made 
up H2O (solvent A) and CH3CN (solvent B) each containing 0.1% v / v TFA, at a 
flow rate of 1 ml / min. The gradient used is: 100% A from 0 (t0) to 25 minutes (t25) 
and then rebalance the initial gradient within 30 minutes (t30). The identification of 
each compound was based on a combination of retention time (tr) and spectral 
matching. 
The crude peptides were purified by preparative HPLC Waters Delta Prep 3000 
equipped with a Jupiter C18 column 15 m eluted with the same mobile phase 
used for analytical HPLC and with a gradient programmed from time to time 
depending on the analytical profile of the crude product. 
In the figures below are shown the crude, purified HPLC profile and mass 
spectrum of compound 25 and [Cys18] N/OFQ-NH2. 
 
 
Figure 39: Crude profile HPLC of the compound 20. 
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Figure 40: Purified profile HPLC Of the compound 20. 
 
 
 
 
Figure 41: MS spectra of the purified compound 20. 
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Figure 42: Crude profile of [Cys
18
] N/OFQ-NH2. 
 
 
Figure 43: Purified profile of [Cys
18
] N/OFQ-NH2. 
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Figure 44: MS spectra of [Cys
18
] N/OFQ-NH2. 
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Peptide 
 
 
Sequence 
 
 
MW 
calculated 
 
[M+H]+   
found 
 
tr HPLC 
 
 
Dermorphin 
 
H-Tyr-DAla-Phe-Gly-Tyr-Pro-Ser-NH2 852.94 853.98 12.31min. 
Leu-
enkephalin 
 
 
Endomorphin 
1 
 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
 
12 
 
13 
 
14 
 
15 
 
16 
 
17 
 
 
18 
 
19 
 
20 
 
21 
 
22 
 
23 
 
 
 
H-Tyr-Gly-Gly-Phe-Leu- NH2 
 
 
H-Tyr-Pro-Trp-Phe- NH2 
 
 
 
H-Tyr-DAla-Phe-Gly-Tyr-Pro-Ser-Lys(Ac)- NH2 
 
 
H-Tyr-Pro-Trp-Phe-Lys(Ac)- NH2 
 
H-Tyr-Pro-Trp-Phe-Gly-Gly-Lys(Ac)- NH2 
 
H-Tyr-Pro-Trp-Phe-O2Oc-Lys(Ac)- NH2 
 
H-Tyr-Pro-Trp-Phe-AVA-Lys(Ac)- NH2 
 
 
H-Tyr-Gly-Gly-Phe- NH2 
 
H-Tyr-Gly-Gly-Phe-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Gly-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Gly-Gly-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-O2Oc-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-AVA-Lys(Ac)- NH2 
 
 
H-Tyr-Gly-Gly-Phe-Lys- NH2 
 
H-Tyr-Gly-Gly-Phe-Lys-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Lys-Gly-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Lys-Gly-Gly-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Lys-O2Oc-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Lys-AVA-Lys(Ac)- NH2 
 
 
H-Tyr-Gly-Gly-Phe-Leu-Arg- NH2 
 
H-Tyr-Gly-Gly-Phe-Leu-Arg-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Leu-Arg-Gly-Gly-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Leu-Arg-O2Oc-Lys(Ac)- NH2 
 
H-Tyr-Gly-Gly-Phe-Leu-Arg-AVA-Lys(Ac)- NH2 
 
554.64 
 
 
610.27 
 
 
 
973,1 
 
 
780.80 
 
894.99 
 
925.54 
 
881.82 
 
 
441.48 
 
611.30 
 
668.33 
 
726.35 
 
757.85 
 
710.82 
 
 
569.66 
 
739.40 
 
796.42 
 
854.45 
 
886.03 
 
838.99 
 
 
710.82 
 
880.49 
 
937.52 
 
995.54 
 
1027.20 
 
 980.16 
 
 
 
 
 
555.31 
 
 
611.17 
 
 
 
974,1 
 
 
781.40 
 
895.80 
 
926.74 
 
882.82 
 
 
442.51 
 
612.50 
 
669.4 
 
726.35 
 
757.20 
 
711.38 
 
 
570.73 
 
740.30 
 
797.42 
 
854.45 
 
885.4 
 
839.47 
 
 
711.77 
 
881.50 
 
938.52 
 
995.54 
 
1026.5 
 
980.57 
 
16.30min. 
 
 
17.20min. 
 
 
 
15.88min 
 
 
15.93min. 
 
12.73min. 
 
17.60min. 
 
13.26min. 
 
 
13.19min. 
 
14.79min. 
 
17.20min. 
 
14.73min. 
 
16.30min. 
 
15.30min. 
 
 
11.82min. 
 
14.05min. 
 
15.83min. 
 
13.26min. 
 
15.08min. 
 
14.13min. 
 
 
15.40min. 
 
17.00min. 
 
16.44min. 
 
16.37min. 
 
17.60min. 
 
16.74min. 
Table 3: List of peptides synthesized with relative MW calculated, MW found and retention times  
in analytical HPLC using a gradient that goes from a 100% H2O at t0 to 100% CH3CN at time t25,  
to return to the initial conditions at t30. 
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4.4 Test of intracellular calcium mobilization 
Cell cultures - for biological assays have been used Chinese Hamster Ovary cells 
(CHO) stably transfected with the human receptor NOP (CHONOP) and MOP 
(CHOMOP) and with a chimeric G protein. This allows the receptor normally coupled 
to Gi protein to activate phospholipase C, producing inositol triphosphate (IP3) and 
diacylglycerol (DAG), obtaining in increased concentrations of intracellular 
calcium62. This protein was created by replacing 5 aminoacids of the C-terminal 
portion of the alpha subunit of Gq protein with the respective aminoacids of Gi, 
obtaining the protein Gαqi5. The cells were cultured in  
Falcon flasks sterile type with screw cap and kept in a suitable medium consisting  
DMEM (Dulbecco's Minimum Essential Medium) and Ham's F-12 (50/50) to which 
they were added hygromycin B and geneticin as selection factors. The cells were 
kept in an incubator at 37 ° C, in ideal conditions of temperature, humidity and in 
the presence of 5% CO2. The day before the experiment the cells were seeded in 
96-well plates with black walls and transparent bottom like type Constar. 
50,000 cells were plated per well in a volume of 100 μl.  
After twenty-four hours, you get a confluence of 90-100% per well. 
FlexStation II - For the study of intracellular calcium mobilization was used the 
equipment FlexStation II (Molecular Devices)(Figure 45). 
The instrument is a bench top fluorometer that measures the change in 
fluorescence due to changes in intracellular levels of cytosolic calcium. The 
variation in the levels of intracellular calcium is expressed as a percentage change 
of the fluorescence values compared to the baseline value, which is determined 
experimentally before the beginning of each experiment. 
The unit consists of:  
-Light source equipped of a xenon lamp (Figure 46)  
-Multichannel Pipettes automatic eight-channel 
- Side trays: 
 higher for disposable tips 
 central plate for drug substances to be tested 
 lower for 96-well plate containing the cells 
The instrument has a system that allows to perform the experiments at defined 
temperature and a software for configuration and management of the instrument 
(SoftMax PRO v.4.8) (Figure 50). 
                                                        
62
 B.R. Conklin, Z. Farfel, K. D. Lustig, D. Julius, H.R. Bourne. Nature, (1993), 363, 274-276. 
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Figure 45: FlexStation®. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: Scheme of the detection system of fluorescence in FlexStation II®. 
 
The instrument is equipped with an optical system consisting of a double 
monochromator and a xenon lamp. 
The xenon lamp, inside the instrument, emits a beam of light at desired 
wavelength (λ) by the operator (488 nm). This light gets to the emission 
monochromator which reflects on the mirror of collimation and then on the wells of 
the plate reading. The cells inside the plate, previously incubated with calcium-
dependent fluorophore, are affected by the light beam from the lamp, emitting 
radiation at a wavelength (λ) of 525 nm. 
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Samples preparation- All compounds tested were dissolved in ddH2O at [1mM] 
and they were stored in aliquots of 20 l at -20°C. The subsequent dilutions were 
done in HBSS characterized by HEPES [20mM] (pH 7.4) and albumin bovine 
serum (BSA) 0.02%. The solutions of the test substances are loaded into a 96-
plate drugs wells (Figure 47) with a V-bottom. The dilutions useful for the 
experiments curve concentration-response are made directly in the micro plate. 
 
 
 
 
 
 
 
 
Figure 47: System of 96-wells where you add the samples to analyse. 
 
Experiment - The day of the experiment the cells plated were incubated 30 
minutes with medium containing the fluorescent dye FLUO-4. 
 
 
 
 
 
 
 
 
 
Figure 48: Chemical formula of the fluorescent dye FLUO-4. 
 
The fluorescent dye FLUO-4-AM penetrates the cell by passive diffusion, due to its 
lipophilic nature; once inside it is degraded by esterases that hydrolyse the ester 
bonds thus freeing the carboxyl functions on capable to chelate the calcium 
mobilized. When the carboxyl functions are free, FLUO-4 is no longer able to 
passively cross the cell membrane, but is expelled through an anion carrier. 
To prevent the expulsion of the fluorescent dye from the cell is added Probenecid, 
a blocker of anion carrier. The calcium complex, excited by the incident 
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electromagnetic radiation is capable of emitting a radiation; whose is proportional 
in intensity to the amount of complex formed. After 30 minutes of incubation the 
liquid loading is aspirated and the wells are filled with a wash solution containing 
the black dye Brilliant Black. This solution has the power of screening, thanks to its 
colour, the background due to fluorescence of the FLUO-4 who is not internalized 
by the cells (Figure 49). 
 
 
 
 
 
 
 
 
 
Figure 49: Experimental protocol of the assay of intracellular calcium mobilization. 
 
The injection of the test substances on cells is automated and it occurs by 
subsequent columns according to a protocol established by the operator. The 
instrument reads the values of the fluorescence data from the mobilization of 
intracellular calcium and returns them as a percentage change from baseline with 
graphical representation of the evolution of fluorescence values (Figure X). 
 
 
 
 
 
 
 
 
 
 
Figure 50: Software SoftMax 4.8 to management the instrument. 
 
Data Analysis - The potency of agonists is expressed in terms of pEC50, which is 
the negative logarithm of the EC50 value. It represents the concentration of agonist 
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where 50% of its maximal effect is observed in defined experimental conditions. 
For the potency values are reported the confidence limits of 95%. 
Emax is the maximal response that an agonist can be produce in particular 
experimental conditions. For the construction of concentration-response curves 
and calculation of pEC50 and Emax it has been used the software GraphPad Prism 
5.0. All data are expressed like average  ± standard error of n experiments. 
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4.5 Synthesis and NMR spectra of the compounds 
Synthesis of Fmoc-AVA-OH (61) 
 
 
 
 
 
 
The 5-aminopentanoic acid (586 mg, 5 mmol) was dissolved in a flask in a solution 
H2O/Dioxane (1:1) (100ml). After it was added Na2CO3 (1.5 g, 15 mmol), the 
reaction was brought to 0°C and  then it is added dropwise Fmoc-Cl (1.17 g, 4.5 
mmol) previously dissolved in dioxane. It was checked the pH with universal 
indicator. The reaction was left for 6 h at r.t.. Subsequently it was introduced 
HClsat. (40ml) and the organic phase was extracted with AcOEt (100ml), 
neutralized with Brine, dried with Na2SO4 and under vacuum to afford the crude 
product 1.49 g.  
Flash chromatography (SiO2) 2:8:0.3 (AcOEt:EtPt:AcOH) to afford 1.85 g of 
compound X (Y=92%)63. 
MS (ESI): [M+H]+= 340.1 
 
tr = 14.87 
 
1H NMR (200 MHz, CDCl3):  9.45 (s, 1H), 7.76 (d, J = 1.5 Hz, 1H), 7.74 (d, J = 
1.5 Hz, 1H), 7.46 – 7.38 (m, 4H), 7.36 – 7.31 (m, 2H), 4.72 – 4.67 (d, 2H), 4.46 (s, 
1H), 4.07 (s, 1H), 3.10 (d, J = 37.3 Hz, 2H), 2.30 – 2.23 (t, 2H), 1.69 – 1.58 (m, 
4H). 
   
 
 
 
 
 
                                                        
63
 L. A. Carpino, G. Y. Han, J. Org. Chem., (1972), 37, 3404-3409. 
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Synthesis of Fmoc- allyl-Asp(OtBu) (62) 
 
 
 
 
 
 
In a flask at 0°C it was added 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-
(tert-butoxy)-4-oxobutanoic acid (2 g, 5 mmol) dissolved in DMF (10ml), WSC (1.1 
g, 5.5 mmol) and Oxyma Pure (782 mg, 5.5 mmol). It was left to stir for 10 min. 
allylamine (314 mg, 5.5 mmol) was dissolved in DMF (3 ml) and than dripped in 
the flask through a syringe. The reaction was left o.n. at r.t.. The DMF was 
evaporated under vacuum. The reaction was dissolved in AcOEt, than extracted 
before with citric acid (10%), after with NaHCO3 5% and finally with Brine. The 
organic layer was dried under vacuum. Flash chromatography (SiO2) 5:5 
(AcOEt:EtPt) to afford 2.1 g of product (Y= 100%). 
 
MS (ESI): [M+H]+= 451.2 
 
tr = 14.68 
 
1H NMR (200 MHz, CDCl3):  7.63 (m, 4H), 7.41 – 7.33 (m, 4H), 6.11 (m, 1H), 
5.18 (m, 2H), 5.00 (t, J= 7.5 Hz, 1H), 4.72 – 4.68 (m, 2H), , 4.04 (m, 2H), 3.11 (dd, 
J = 8.7, 3.4 Hz, 2H), 1.42 (s, 9H). 
 
 
 
 
 
 
 
 
 
 
 
C26H30N2O5 
Mol. Wt.: 450,5 
HN CHC NH
O
C
O
O
O
O
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Peptide   Sequence 
Mw 
calculated 
 Mw 
found  
  tr Thiol-ene between 
26 AGGFC Ala-Gly-Gly-Phe-Cys-NH2   452.54     452.9 10.3 
Thiol-ene with ally-glucose(43-43bis) and with 
allyl-Asp(O
t
Bu)(44-44bis) 
27 AGFGC Ala-Gly-Phe-Gly-Cys-NH2 452.54 452.9 10.43 Incomplete, reaction under study 
28 AGGHC Ala-Gly-Gly-His-Cys-NH2 442.5 443.2 9.81 Thiol-ene with ally-glucose(45-45bis) 
29 AGHGC Ala-Gly-His-Gly-Cys-NH2 442.5 442.9 9.98 
Thiol-ene with ally-glucose(46-46bis) and with 
allyl-Asp(O
t
Bu)(47-47bis) 
30 AGGWC Ala-Gly-Gly-Trp-Cys-NH2 491.57 492.2 10.67 
Thiol-ene with ally-glucose(48-48bis) 
31 AGWGC Ala-Gly-Trp-Gly-Cys-NH2 491.57 492.1 10.74 Incomplete, reaction under study 
32 AGGYC Ala-Gly-Gly-Tyr-Cys-NH2 468.53 468.8 10.89 Incomplete, reaction under study 
33 FGGTC Phe-Gly-Gly-Thr-Cys-NH2 482.56 483.4 9.60 Thiol-ene with ally-glucose(49-49bis) 
34 FGTGC Phe-Gly-Thr-Gly-Cys-NH2 482.56 483.43 9.34 Thiol-ene with ally-glucose(50-50bis) 
35 FGGNC Phe-Gly-Gly-Asn-Cys-NH2 495.56 495.58 8.48 Thiol-ene with ally-glucose(51-51bis) 
36 FGNGC Phe-Gly-Asn-Gly-Cys-NH2 495.56 496.7 8.50 
Thiol-ene with ally-glucose(52-52bis) and 
Dodecene(commercially available)(53-53bis) 
37 FGGQC Phe-Gly-Gly-Gln-Cys-NH2 509.59 510.65 8.86 Thiol-ene with ally-glucose(54-54bis) 
38 FGQGC Phe-Gly-Gln-Gly-Cys-NH2 509.59 510.38 8.83 Thiol-ene with ally-glucose(55-55bis) 
39 FGGEC Phe-Gly-Gly-Glu-Cys-NH2 510.57 511.66 9.11 Thiol-ene with ally-glucose(56-56bis) 
40 FGEGC Phe-Gly-Glu-Gly-Cys-NH2 510.57 511.66 9.13 Thiol-ene with ally-glucose(57-57bis) 
41 FGGDC Phe-Gly-Gly-Asp-Cys-NH2 496.55 497.77 8.64 Thiol-ene with ally-glucose(58-58bis) 
42 FGDGC Phe-Gly-Asp-Gly-Cys-NH2 496.55 497.64 8.96 Thiol-ene with ally-glucose(X) 
      Table 4: List of peptides synthesized with relative MW calculated, MW found and retention times  
in analytical HPLC using a gradient that goes from a 100% H2O at t0 to 100% CH3CN at time t25,  
to return to the initial conditions at t30. 
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Peptide  Mw Thiol-ene products  
26 AGGFC         
 
                  43                               43bis                                44                         44bis                               
28 AGGHC  
 
 
   45                                   45bis 
29 AGHGC      
         
                  46                                  46bis                               47                                  47bis 
30 AGGWC 
 
  
 
      
             48                                    48bis                                                       
33 FGGTC  
 
                 49                                    49bis  
34 FGTGC   
     
                 50                                    50bis 
35 FGGNC   
 
             51                                         51bis 
36 FGNGC  
  
          52                                         52bis                         53                             53bis 
37 FGGQC  
  
          54                                          54bis  
38 FGQGC  
 
          55                                           55bis  
39 FGGEC  
  
             56                                            56bis 
40 FGEGC  
  
             57                                             57bis 
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C30H47N7O12S
Mol. Wt.: 729,8
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Table 5: Summary of compounds obtained through the Thiol-ene reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 FGGDC  
  
              
            58                                               58bis             
42 FGDGC  
 
  
            59                                               59bis 
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Synthesis of allyl-glucose (63) 
 
 
 
 
 
To a suspension of D-glucose (2 g, 11.10 mmol) in anhydrous ethanol (40 ml) was 
added BF3 etherate (233 m, 1,64 mmol). After it was introduced Ac2O (20 ml) and 
pyridine (50 ml) and it was left to stir o.n. at r.t.64. 
The solution was concentrated and than extracted with AcOEt/ NaOH(2N) (basic 
wash) and AcOEt/ HCl(1M) (acid wash). The organic phase was concentrated 
under vacuum to obtain the crude product. 
Flash chromatography (SiO2) 5:5 (Et2O/EtPt) to afford 134.2 mg (Y=21%). 
In order to have (2R,3R,4S,5S,6R)-2-(allyloxy)-6-(hydroxymethyl)tetrahydro-2H-
pyran-3,4,5-triol it was prepared a solution with Na° dissolved in MeOH and it was 
added few ml at a time with the sugar. 
The reaction was checked by TLC 5:5 (Et2O/EtPt). 
Finally the reaction was quenched with Amberlite until the pH=7. The mixture 
obtained was filtered through a gooch funnel, dried under vacuum to afford 76.1 
mg of compound X (Y= 54%). 
 
1H NMR (400 MHz, D2O)  5.95 (dddd, J = 16.9, 10.4, 6.4, 5.6 Hz, 1H), 5.35 (dq, J 
= 17.2, 1.6 Hz, 1H), 5.26 (ddd, J = 10.4, 1.9, 0.9 Hz, 1H), 4.47 (d, J = 8.0 Hz, 1H), 
4.36 (ddt, J = 12.7, 5.6, 1.4 Hz, 1H), 4.25 -4.13 (m, 1H), 3.89 (dd, J = 12.3, 2.2 Hz, 
1H), 3.68 (dd, J = 12.3, 5.9 Hz, 1H), 3.45 (t, J = 9.1 Hz, 1H), 3.42 - 3.38 (m, 1H), 
3.35 (dd, J = 9.8, 8.9 Hz, 1H), 3.25 (dd, J = 9.3, 8.0 Hz, 1H). 
 
13C NMR (100 MHz, D2O) 133.19, 118.66, 101.08, 75.82, 75.70, 73.02, 70.53, 
69.57, 60.66. 
 
 
 
 
 
                                                        
64
 J. M. J. Tronchet, M. Zsély, M. Geoffroy, Carbohydrate Research, 275, (1995), 245-258. 
O
OH
O
OH
HO
HO
C9H16O6 
Mol. Wt.: 220,2 
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General procedure of synthesis for Thiol-ene reaction 
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NMR study first series of pentapeptide 
1H AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4) 7.29 (d, J = 1.3 Hz, 2H), 7.28 (s, 2H), 7.25 - 
7.18 (m, 1H), 4.64 (dd, J = 8.9, 6.0 Hz, 1H), 4.43 (dd, J = 7.5, 5.1 Hz, 1H), 4.06 - 
3.99 (m, 1H), 3.97 - 3.85 (m, 3H), 3.76 (d, J = 16.7 Hz, 1H), 3.19 (dd, J = 13.9, 6.1 
Hz, 1H), 3.01 (dd, J = 13.8, 8.9 Hz, 1H), 2.90 (dd, J = 13.9, 5.1 Hz, 1H), 2.81 (dd, 
J = 13.9, 7.6 Hz, 1H), 1.54 (d, J = 7.1 Hz, 3H). 
 
13C-DEPT AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)174.29, 173.68, 171.97, 171.68, 138.27, 
130.35, 129.61, 127.95, 56.97, 56.45, 50.31, 43.68, 43.41, 38.39, 26.64, 17.31. 
H2N
O
H
N
N
H
O
O
N
H
O
NH2
SH
H
N
O
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COSY AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
HMBC AGGFC (26) 
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HMQC AGGFC (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H Thiol-ene I product (43) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.29 - 7.28 (m, 1H), 7.28 (s, 2H), 4.66 (dd, J = 
9.1, 5.7 Hz, 1H), 4.47 (dd, J = 8.0, 5.9 Hz, 1H), 4.07 - 3.92 (m, 2H), 3.91 - 3.83 (m, 
2H), 3.76 (d, J = 16.7 Hz, 1H), 3.71 - 3.62 (m, 1H), 3.22 - 3.10 (m, 2H), 3.03 - 2.93 
(m, 1H), 2.80 (dd, J = 13.9, 8.0 Hz, 1H), 2.70 (t, J = 7.2 Hz, 2H). 
 
MS (ESI): [M+H]+= 672.7 
 
H2N
O
H
N
N
H
O
O
N
H
O
NH2
S
H
N
O
O
HO
O
OH
OH
OH
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HRMS spectra of Thiol-ene primary product. 
 
 
 
 
 
 
1H Thiol-ene II product (43bis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (ESI): [M+H]+= 688.7 
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HRMS spectra of Thiol-ene secondary  product. 
 
 
 
 
1H AGFGC (27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.34 - 7.17 (m, 5H), 4.50 (ddd, J = 8.3, 5.9, 1.9 
Hz, 2H), 4.04 - 3.93 (m, 3H), 3.82 (dd, J = 16.6, 1.2 Hz, 1H), 3.70 (dd, J = 16.7, 
1.2 Hz, 1H), 3.18 (dd, J = 13.8, 6.2 Hz, 1H), 3.03 - 2.92 (m, 1H), 2.92 - 2.85 (m, 
2H), 1.50 (dd, J = 7.1, 1.3 Hz, 3H). 
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N
H
O
NH2
SH
N
H
O
H
N
O
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13C AGFGC (27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.64, 174.30, 171.62, 171.53, 171.19, 
138.27, 130.24, 129.55, 127.89, 56.93, 56.81, 50.24, 43.78, 43.20, 38.20, 26.79, 
17.41. 
 
 
DEPT AGFGC (27) 
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COSY AGFGC (27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC AGFGC (27) 
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HMQC AGFGC (27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H AGGHC (28)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  8.77 (d, J = 1.4 Hz, 1H), 7.37 (d, J = 1.4 Hz, 
1H), 4.76 (dd, J = 7.6, 5.8 Hz, 2H), 4.47 (dd, J = 7.7, 4.9 Hz, 1H), 4.04 (q, J = 7.1 
Hz, 1H), 3.97 - 3.88 (m, 3H), 3.83 (d, J = 16.7 Hz, 1H), 3.20 (ddd, J = 15.3, 7.6, 
0.8 Hz, 1H), 3.02 - 2.74 (m, 2H), 1.54 (d, J = 7.1 Hz, 3H). 
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13C AGGHC (28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.60, 172.10, 172.04, 171.95, 171.71, 
135.07, 130.64, 118.84, 57.08, 53.57, 50.33, 43.76, 43.63, 27.99, 26.79, 17.30. 
 
 
 
 
DEPT AGGHC (28) 
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COSY AGGHC (28) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
HMBC AGGHC (28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ferrara’s project                                                                                                  Experimental section 
 112 
HMQC AGGHC (28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
1H AGHGC (29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  8.78 (s, 1H), 7.41 (s, 1H), 4.70 (dt, J = 13.1, 
6.1 Hz, 1H), 4.53 (dd, J = 7.4, 5.0 Hz, 1H), 3.96 (qt, J = 16.0, 8.6 Hz, 5H), 3.40 -
3.32 (m, 1H), 3.19 (dd, J = 15.4, 7.2 Hz, 1H), 2.90 (qd, J = 14.1, 6.5 Hz, 2H), 1.53 
(d, J = 7.0 Hz, 3H). 
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13C AGHGC (29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.59, 172.60, 171.99, 171.92, 171.88, 
171.32, 135.01, 130.72, 118.89, 56.90, 53.82, 50.23, 43.58, 43.50, 27.74, 26.89, 
17.41. 
 
 
DEPT AGHGC (29) 
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COSY AGHGC (29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC AGHGC (29) 
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HMQC AGHGC (29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H AGGWC (30) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.69 -7.53 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
7.17 (s, 1H), 7.13 - 7.07 (m, 1H), 7.02 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 4.67 (dd, J = 
7.7, 6.3 Hz, 1H), 4.39 (dd, J = 7.2, 5.2 Hz, 1H), 4.02 (q, J = 7.1 Hz, 1H), 3.94 (dd, 
J = 16.6, 6.6 Hz, 2H), 3.89 - 3.74 (m, 2H), 3.35 (d, J = 6.4 Hz, 1H), 3.21 (dd, J = 
14.6, 7.7 Hz, 1H), 2.85 - 2.66 (m, 2H), 1.53 (d, J = 7.0 Hz, 3H). 
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13C-DEPT AGGWC (30) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.39, 174.17, 171.94, 171.83, 171.76, 
138.00, 128.60, 124.87, 122.58, 119.97, 119.30, 112.42, 110.54, 56.83, 56.07, 
50.30, 43.59, 43.55, 28.39, 26.50, 17.32. 
 
 
 
COSY AGGWC (30) 
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HMBC AGGWC (30) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC AGGWC (30) 
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1H AGWGC (31) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.63 -7.53 (m, 1H), 7.39 - 7.28 (m, 1H), 7.14 
(s, 1H), 7.09 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.02 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 
4.55 (dd, J = 7.6, 6.7 Hz, 1H), 4.49 (dd, J = 7.3, 5.3 Hz, 1H), 4.03 - 3.91 (m, 3H), 
3.84 (d, J = 16.6 Hz, 1H), 3.65 (d, J = 16.7 Hz, 1H), 3.18 (ddd, J = 14.5, 7.6, 0.7 
Hz, 1H), 2.92 - 2.81 (m, 2H), 1.48 (d, J = 7.1 Hz, 4H). 
  
 
13C AGWGC (31) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, , Methanol-d4)  174.87, 174.68, 171.70, 171.56, 171.19, 
138.07, 128.70, 124.69, 122.50, 119.87, 119.18, 112.36, 110.59, 56.87, 56.53, 
50.24, 43.87, 43.31, 28.31, 26.76, 17.39. 
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DEPT AGWGC (31) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
COSY AGWG (31) 
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HMBC AGWGC (31) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC AGWGC (31) 
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1H AGGYC (32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.09 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 
2H), 4.57 (dd, J = 8.7, 6.1 Hz, 1H), 4.42 (dd, J = 7.5, 5.1 Hz, 1H), 4.07 -3.98 (m, 
1H), 3.99 - 3.85 (m, 3H), 3.77 (d, J = 16.7 Hz, 1H), 3.08 (dd, J = 13.9, 6.1 Hz, 1H), 
2.98 - 2.86 (m, 2H), 2.81 (dd, J = 13.9, 7.5 Hz, 1H), 1.54 (d, J = 7.1 Hz, 3H). 
 
 
 
 
13C AGGYC (32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.52, 174.05, 172.15, 171.87, 157.61, 
131.55, 128.99, 116.55, 57.15, 56.91, 50.50, 43.85, 43.62, 37.81, 26.82, 17.50. 
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DEPT AGGYC (32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY AGGYC (32) 
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HMBC AGGYC (32) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
HMQC AGGYC (32) 
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NMR study second series of pentapeptide 
1H FGGTC (33) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.44 -7.11 (m, 5H), 4.51 (dt, J = 7.4, 5.1 Hz, 
1H), 4.39 (d, J = 4.0 Hz, 1H), 4.24 (qd, J = 6.4, 4.1 Hz, 1H), 4.19 - 4.11 (m, 2H), 
4.09 - 3.70 (m, 2H), 3.29 - 3.22 (m, 1H), 3.06 (dd, J = 14.1, 8.3 Hz, 1H), 2.99 - 
2.78 (m, 2H), 1.42 (d, J = 6.6 Hz, 1H), 1.22 (d, J = 6.4 Hz, 3H). 
 
13C FGGTC (33) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.58, 172.50, 172.10, 171.73, 170.49, 
135.65, 130.46, 130.17, 128.91, 68.19, 60.30, 56.86, 55.93, 43.63, 43.46, 38.45, 
26.66, 19.95. 
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DEPT FGGTC (33) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY FGGTC (33) 
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HMBC FGGTC (33) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC FGGTC (33) 
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THIOL-ENE COMPOUND (49) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (49-49bis). 
 
 
1H FGTGC (34) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.42 -7.25 (m, 5H), 4.50 (dd, J = 7.5, 5.1 Hz, 
1H), 4.32 - 4.23 (m, 2H), 4.16 (dd, J = 8.2, 6.3 Hz, 1H), 4.06 (dd, J = 34.7, 16.6 
Hz, 2H), 3.87 (d, J = 16.6 Hz, 2H), 3.27 (dd, J = 14.1, 6.3 Hz, 1H), 3.07 (dd, J = 
14.1, 8.2 Hz, 1H), 2.87 (qd, J = 13.9, 6.4 Hz, 1H), 1.22 (d, J = 6.3 Hz, 4H). 
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13C-DEPT FGTGC (34) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.60, 173.53, 171.72, 171.62, 170.45, 
135.58, 130.48, 130.12, 128.87, 68.23, 60.68, 56.85, 55.82, 43.81, 43.47, 38.51, 
26.83, 20.03. 
 
COSY FGTGC (34) 
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HMBC FGTGC (34) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC FGTGC (34) 
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THIOL-ENE COMPOUND (50) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (50-50bis). 
 
 
 
1H FGGNC (35) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.49 -7.13 (m, 5H), 4.73 (t, J = 6.5 Hz, 1H), 
4.46 (dd, J = 7.6, 4.8 Hz, 1H), 4.16 (dd, J = 8.4, 6.3 Hz, 1H), 4.05 - 3.77 (m, 4H), 
3.30 - 3.24 (m, 1H), 3.13 - 3.02 (m, 1H), 2.98 - 2.80 (m, 3H), 2.75 (dd, J = 15.7, 
6.4 Hz, 1H). 
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13C FGGNC (35) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.89, 174.70, 173.24, 171.83, 171.66, 
170.64, 135.63, 130.47, 130.17, 128.92, 57.05, 55.91, 51.79, 43.73, 43.64, 38.45, 
37.26, 26.59. 
 
DEPT FGGNC (35) 
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COSY FGGNC (35) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC FGGNC (35) 
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HMQC FGGNC (35) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THIOL-ENE COMPOUND (51) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (51-51bis). 
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1H FGNGC (36) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.34 (dt, J = 23.5, 7.4 Hz, 5H), 4.67 (t, J = 5.8 
Hz, 1H), 4.49 (t, J = 6.6 Hz, 1H), 4.16 (dd, J = 8.2, 6.2 Hz, 1H), 4.03 (dd, J = 16.7, 
8.5 Hz, 2H), 3.81 (dd, J = 16.7, 6.7 Hz, 2H), 3.29 - 3.23 (m, 1H), 3.08 (dd, J = 
14.1, 8.3 Hz, 1H), 2.90 (d, J = 6.8 Hz, 3H), 2.81 (dd, J = 25.0, 5.8 Hz, 1H). 
 
13C FGNGC (36) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.87, 174.06, 171.91, 171.19, 170.59, 
135.62, 130.48, 130.14, 128.89, 57.27, 55.87, 51.63, 44.01, 43.62, 38.50, 37.20, 
26.78. 
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DEPT FGNGC (36) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY FGNGC (36) 
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HMBC FGNGC (36) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC FGNGC (36) 
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THIOL-ENE COMPOUND (52) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (52-52bis). 
 
 
 
 
THIOL-ENE COMPOUND (53) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (53-53bis). 
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1H FGGQC (37) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.44 -7.26 (m, 5H), 4.46 (dd, J = 7.8, 5.0 Hz, 
1H), 4.35 (dd, J = 8.6, 5.5 Hz, 1H), 4.16 (dd, J = 8.3, 6.1 Hz, 1H), 3.98 (dd, J = 
16.6, 7.2 Hz, 2H), 3.85 (dd, J = 16.6, 5.7 Hz, 2H), 3.31 - 3.24 (m, 1H), 3.07 (dd, J 
= 14.2, 8.4 Hz, 1H), 2.94 (dd, J = 13.9, 5.0 Hz, 1H), 2.84 (dd, J = 13.9, 7.8 Hz, 
1H), 2.34 (t, J = 7.7 Hz, 2H), 2.19 - 1.94 (m, 2H). 
 
13C FGGQC (37) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz Methanol-d4)  177.89, 174.56, 173.87, 172.05, 171.88, 
170.75, 135.57, 130.53, 130.16, 128.92, 56.95, 55.86, 54.74, 43.87, 43.71, 38.44, 
32.43, 28.21, 26.74. 
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DEPT FGGQC (37) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY FGGQC (37) 
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HMBC FGGQC (37) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THIOL-ENE COMPOUND (54) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (54-54bis). 
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1H FGQGC (38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.43 -7.21 (m, 5H), 4.49 (dd, J = 7.3, 5.0 Hz, 
1H), 4.29 (dd, J = 7.9, 5.2 Hz, 1H), 4.17 (t, J = 7.3 Hz, 1H), 4.11 - 3.68 (m, 4H), 
3.26 (dd, J = 14.0, 6.7 Hz, 1H), 3.08 (dd, J = 13.9, 8.0 Hz, 1H), 2.88 (t, J = 6.7 Hz, 
2H), 2.49 - 2.26 (m, 2H), 2.20 - 1.92 (m, 2H). 
 
13C-DEPT FGQGC (38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  178.16, 174.66, 174.49, 171.66, 171.40, 
170.41, 135.63, 130.47, 130.13, 128.88, 56.90, 56.00, 55.02, 43.80, 43.44, 38.42, 
32.25, 27.92, 26.81. 
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COSY FGQGC (38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC FGQGC (38) 
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HMQC FGQGC (38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THIOL-ENE COMPOUND (55) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (55-55bis). 
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1H FGGEC (39) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.45 - 7.25 (m, 5H), 4.46 (dd, J = 7.7, 5.1 Hz, 
1H), 4.39 (dd, J = 8.7, 5.5 Hz, 1H), 4.17 (dd, J = 8.2, 6.3 Hz, 1H), 3.98 (dd, J = 
16.6, 6.4 Hz, 2H), 3.84 (dd, J = 16.6, 7.8 Hz, 2H), 3.27 (dd, J = 14.1, 6.3 Hz, 1H), 
3.08 (dd, J = 14.1, 8.2 Hz, 1H), 2.94 (dd, J = 13.9, 5.1 Hz, 1H), 2.84 (dd, J = 13.9, 
7.7 Hz, 1H), 2.48 - 2.40 (m, 2H), 2.14 (dddd, J = 13.7, 8.2, 7.1, 5.5 Hz, 1H), 2.03 - 
1.93 (m, 1H). 
 
13C FGGEC (39) 
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13C NMR (100 MHz, Methanol-d4)  176.71, 174.52, 173.81, 172.04, 171.77, 
170.68, 135.54, 130.51, 130.14, 128.90, 56.88, 55.85, 54.54, 43.72, 43.62, 38.42, 
31.13, 27.74, 26.67. 
 
 
 
DEPT FGGEC (39) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY FGGEC (39) 
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HMBC FGGEC (39) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC FGGEC (39) 
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THIOL-ENE COMPOUND (56) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (56-56bis). 
 
 
1H FGEGC (40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.43 -7.25 (m, 5H), 4.50 (dd, J = 7.3, 5.2 Hz, 
1H), 4.34 (dd, J = 8.6, 5.4 Hz, 1H), 4.17 (dd, J = 8.2, 6.2 Hz, 1H), 4.01 (dd, J = 
18.6, 16.6 Hz, 2H), 3.83 (dd, J = 16.6, 8.9 Hz, 2H), 3.32 - 3.22 (m, 1H), 3.07 (dd, J 
= 14.1, 8.2 Hz, 1H), 2.96 - 2.81 (m, 2H), 2.44 (t, J = 7.4 Hz, 2H), 2.21 - 2.10 (m, 
1H), 1.98 (ddt, J = 14.2, 8.8, 7.3 Hz, 1H). 
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13C FGEGC (40) 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  176.57, 174.67, 174.46, 171.64, 171.35, 
170.34, 135.58, 130.48, 130.12, 128.87, 56.82, 55.84, 54.68, 43.80, 43.35, 38.47, 
31.08, 27.66, 26.76. 
 
DEPT FGEGC (40) 
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COSY FGEGC (40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC FGEGC (40) 
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HMQC FGEGC (40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THIOL-ENE COMPOUND (57) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HRMS spectra of Thiol-ene product (57-57bis). 
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1H FGGDC (41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.47 - 7.22 (m, 5H), 4.75 (t, J = 6.7 Hz, 1H), 
4.47 (dd, J = 7.5, 4.9 Hz, 1H), 4.15 (dd, J = 8.4, 6.2 Hz, 1H), 4.04 - 3.75 (m, 4H), 
3.29 - 3.23 (m, 1H), 3.10 - 2.76 (m, 5H). 
 
13C FGGDC (41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  173.17, 172.74, 171.65, 170.34, 169.16, 
134.21, 129.03, 128.74, 127.50, 55.55, 54.48, 50.03, 42.24, 42.15, 37.02, 34.78, 
25.15. 
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DEPT FGGDC (41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY FGGDC (41) 
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HMBC FGGDC (41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMQC FGGDC (41) 
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THIOL-ENE COMPOUND (58) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
HRMS spectra of Thiol-ene product (58-58bis). 
 
 
1H FGDGC (42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Methanol-d4)  7.42 - 7.26 (m, 5H), 4.75 - 4.64 (m, 1H), 4.50 
(dd, J = 7.7, 5.4 Hz, 1H), 4.15 (dd, J = 8.3, 6.2 Hz, 1H), 4.04 (dd, J = 16.6, 5.3 Hz, 
2H), 3.81 (dd, J = 16.6, 3.3 Hz, 2H), 3.29 - 3.22 (m, 1H), 3.07 (dd, J = 14.1, 8.3 
Hz, 1H), 2.89 (dd, J = 7.0, 5.3 Hz, 4H). 
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13C FGDGC (42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, Methanol-d4)  174.72, 174.35, 173.76, 171.72, 171.31, 
170.52, 135.60, 130.47, 130.15, 128.91, 56.97, 55.84, 51.44, 44.01, 43.49, 38.52, 
36.31, 26.78. 
 
DEPT FGDGC (42) 
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COSY FGDGC (42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC FGDGC (42) 
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HMQC FGDGC (42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THIOL-ENE COMPOUND (59) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (59-59bis). 
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Thiol-ene with a NOP ligand and allyl-glucose 
The reaction gave the expected result. 
COMPOUND (60) 
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COMPOUND (60bis) 
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THIOL-ENE COMPOUND (60-60bis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRMS spectra of Thiol-ene product (60-60bis). 
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PART 2 
4.1 General Methods 
Commercially available reagents were purchased from Alfa Aesar, Fisher, Sigma-
Aldrich, Tocris bioscience and VWR. All of these chemicals were the highest grade 
and used without further purification.  
Flash chromatography was performed on Silica gel Si 60 (40-63 m). 
Analytical Thin Layer Chromatographies (TLC) were performed Merk silica gel 
glass plate  (60 A, particle size 40-63 m). 
NMR data were recorded on Bruker ADVANCE III (University of Aberdeen) for 1H 
at 400 MHz, for 13C at 100 MHz. All chemical shifts () are expressed in parts per 
million and coupling costant (J) are given in Hertz. Abbreviations used for peak 
multiplicity are: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quadruplet; 
quint, quintuplet; m, multiplet.  
LC-MS experiments were performed on an Agilent Technologies 1200 Series 
HPLC system equipped with a DAD and a 6120 MS detector composed by a ESI 
ionization source and a single quadrupole mass selective detector using a 
Analytical C18 RP colomun (Phenomenex Luna, C18(2) 250 mm × 4.60 mm, 5 , 
100 Ǻ).  
FUSION-SL Advance 4.2 MP for Fluorescence and Chemiluminescence 4.2/10 
megapixel CCD camera with fixed focal length lens, linked to FUSION-CAPT-
Software. 
JASCO J-600 spectropolarimeter using a quartz cell with 1-mm path length, under 
PC control with an additional (near IR) photomultiplier which allows data to be 
gathered over the wavelength range from 180 nm to 1000 nm, a cryostat 
accessory allows spectra to be recorded at temperatures down to -196 (or 15 °C 
for CD analyses) from University of Glasgow (Scotland). 
Image J Software 
Image J software is a full-featured, multifunction computer program to analyze and 
edit digital images of electrophoresis gels and blots that were acquired using gel 
documentation imagers or scanners. 
The software comprises a complete set of easy-to-use research tools for the 
quantitative digital analysis of image data from electrophoresis gels and Western 
blots. The software uses a powerful algorithm to automatically select and identify 
lanes and band-boundaries for calculation of migration distances or densitometry. 
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It can provide molecular weight determination, relative and absolute quantity, and 
purity calculation. 
 
4.2 EMSA (electrophoretic mobility shift-assay) 
Electrophoresis is a simple, rapid, and sensitive analytical tool for separating 
proteins and nucleic acids based on their physical characteristics (as mass, 
isoelectric point). Most biological molecules carry a net charge at any pH other 
than their isoelectric point and migrate at a rate proportional to their charge density 
in an electrical field. The mobility of a biological molecule through an electric field 
depends on the following factors: 
Field strength, net charge on the molecule, size and shape of the molecule, ionic 
strength and properties of the medium through which the molecules migrate (e.g., 
viscosity, pore size).  
Support Matrix. Polyacrylamide and agarose are two types of support matrices 
used in electrophoresis. The support matrix is a porous media that acts as a 
molecular sieve. The sieving function depends on the pore size and concentration 
of the matrix. Agarose has a large pore size and is ideal for separating macro- 
molecules such as nucleic acids and protein complexes. Polyacrylamide has a 
smaller pore size and is ideal for separating proteins and smaller nucleic acids. 
Polyacrylamide Gel Electrophoresis. Polyacrylamide gels are formed by the 
polymerization of acrylamide monomers into long chains, crosslinked by 
bifunctional compounds such as N,N-methylene-bisacrylamide (bis) that react with 
the free functional groups at the chain termini. The pore size of the gel is governed 
by the concentration of acrylamide and bisacrylamide with a higher acrylamide 
concentration creating smaller pore sizes, allowing resolution of low molecular 
weight molecules. 
Buffer Systems. Electrophoresis is performed using continuous or discontinuous 
buffer systems. In this case continuous buffer systems were utilized as a single 
buffer for the gel and the running buffer was used. 
Electrophoresis Sample Conditions.  
Non-Denaturing (Native): Electrophoresis is performed under non-denaturing 
(native) conditions using buffer systems that maintain the native protein 
conformation, cohesion of subunits, and biological activity. During native 
electrophoresis, proteins are separated based on their charge to mass ratios. 
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Novex
 
Gel Specifications. The Novex Pre-Cast Gel cassette is 10 cm × 10 cm in 
size, and designed for use with the XCell SureLockTM Mini-Cell.  
 
4.3 Nucleic Acid Separation Applications 
Gel shift assays. The Novex® 6% DNA Retardation Gels are used to perform gel 
shift assays using polyacrylamide TBE Gels, which provide high-resolution 
analysis of restriction digests and PCR products. The TBE Gels give sharp, 
intense bands and provide separations of double-strand DNA fragments. 
Preparation of oligonucleotide 
The oligonucleotides purchased are diluted to achieve a concentration of 100 M 
with ddH2O or DMSO (Sigma Aldrich), depending on the solubility of the 
compound.  Aliquots are stored at– 20°C. 
Preparation of TE Buffer 
Solution of 10 mM of Tris-HCl (pH 8) and 1 mM of EDTA. Finally the solution is 
sterilized by autoclaving. 
PCR Block Program for Quadruplex Folding 
 
Stage 1 (1 cycle): 
 Temperature 95 °C 
 Time 5 minutes 
Stage 2 (90 cycles): 
 Temperature 95°C  
 Time 1 minutes 
Stage 3 (1 cycle): 
 Hold at 4 °C 
 
4.3.1 Protocol for Novex DNA Retardation gel 
 Prepare and Pre-Run Gel 
1. A native gel 0.5X TBE (solution stock is 5X TBE:  100 ml of TBE 5X 
is brought in 900 ml of ddH2O) is prepared. 
   The gel was placed in the electrophoresis unit  and it was clamped to 
obtain a seal. The inner chamber was filled with 0.5X TBE (to just above the 
bottom of the wells), which reduces heat during electrophoresis.  Flush 
wells and pre-electrophoresis of the gel for 60 minutes. 100V is applied. 
 Prepare the sample for electrophoresis 
1.   2 µl of Hi-density TBE buffer  is added. 
2.   10 µl are put in the wells of electrophoresis. 
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 Electrophoresis of sample 
1.   Current to electrophoresis gel is switched for 63 minutes and 100V is 
applied. 
 Electrophoresis Transfer of Binding Reactions to Nylon Membran 
1.  0.5X TBE buffer was prepared and cooled at -10°C with ice or a 
circulating water bath. 
2.  Nylon membrane is soaked in 0.5X TBE for at least 10 minutes. 
 Transferring on gel 
  At the end of electrophoresis each of the three bonded sides are 
separated from the cassette by inserting the Gel Knife  into the gap 
between the two plastic plates until they will be divided.  
 DNA transfer 
1.  All the components must be wet with 0.5X TBE cooled and they are 
put in this order in the block: 
 
 
 
 
 
 
Figure 29: The block is positioned within the system as displayed above. 
2.  The inner chamber is filled with 0.5X TBE cooled to a height several 
millimetres above the top of the wells in the gel. Outside of the tank is filled 
with 600 ml di ddH2O (to just above the bottom of the wells), which reduces 
heat during electrophoresis. 
3.  Transfer of DNA on to the membrane is carried out for 60 minutes at 
380A.  
4.  When the transfer is complete, the membrane is placed with the 
bromophenol blue side up on a dry paper towel.. Buffer on the membrane 
surface is allowed to absorb into the membrane.  
 Crosslink Transferred DNA to Membrane 
1.  The membrane face down is crosslinked for 10 minutes on a UV 
transilluminator equipped with 312 nm bulbs. 
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 Detect Biotin-labelled DNA  
The recommended volumes are for an 8×10 cm membrane.  All blocking  and 
detection incubations are performed in clean trays or in plastic weigh boats on an 
orbital shaker. 
1.  The Blocking Buffer and the 4X Wash Buffer are gently warmed to 
37-50°C in a water bath until all particulate is dissolved. These buffers may 
be used between room temperature and 50°C as long as all particulate 
remains in solution. The Substrate Equilibration Buffer may be used 
between 4°C and room temperature. 
2.  The membrane is added to 20 ml of Blocking Buffer and it is 
incubated for 15 minutes with gentle shaking. 
3.  Conjugate/blocking buffer solution is prepared by adding 67 µl 
Stabilized Streptavidin-Horseradish Peroxidase Conjugate to 20 ml 
Blocking Buffer (1:300 dilution) 
4.  Blocking Buffer is decanted from the membrane and it is replaced 
with the conjugate/blocking solution. The membrane is incubated in the 
conjugate/blocking buffer solution for 15 minutes with gentle shaking. 
5.  1X wash solution is done by adding 40 ml of 4X Wash Buffer to 120 
ml of ddH2O. 
6.  The membrane is transferred to a new container and it is rinsed 
briefly with 20 ml of 1X wash solution (by hand). 
7.  The membrane is washed four times for 5 minutes each in 20 ml of 
1X wash solution with gentle shaking. 
8.  The membrane is moved to a new container and it is introduced 30 
ml of Substrate Equilibration Buffer. The membrane is incubated for 5 
minutes with gentle shaking. 
9.   Substrate Working Solution is done by adding 6 ml 
Luminol/Enhancer Solution to 6 ml Stable Peroxide Solution. 
10. The membrane is removed from the Substrate Equilibration Buffer, 
carefully blotting an edge of the membrane on a paper towel to take away 
the excess buffer. The membrane is placed in a clean container or into a 
clean sheet of plastic wrap on a flat surface. 
11. The Substrate Working Solution is put onto the membrane so that it 
is completely coveres both surfaces. Alternatively, the membrane is left in 
the substrate solution for 5 minutes without shaking. 
Aberdeen’s project                                                                                            Experimental section 
 165 
12.  The membrane is removed from the Working Solution and it is 
blotted an edge of the membrane on a paper towel for 2-5 seconds to 
delete excess buffer. 
13. The moist membrane is wrapped in plastic wrap, avoiding bubbles 
and wrinkles. 
14. The membrane is exposed to an appropriately equipped CCD 
camera, or place the membrane in a film cassette and expose to X-ray film 
for 2-5 minutes. The film is developed according to manufacturer’s 
instructions. Exposure time may be adjusted to obtain the desired signal. 
 
4.4 Biochemistry: EMSA  
Series of oligonucleotides analyzed to find the best concentration to work with 
EMSA. 
 
Tel.(1xG4)                     
[Btn]TTAGGGTTAAGGGTTAGGGTT
AGGG 
Tel.(2xG4)                    
[Btn]TTAGGGTTAAGGGTTAGGGTTAGGGTTAGGGTTAAGGGTTAGG
GTTAGGG 
ILPR-1(1xG4)                
[Btn]ACAGGGGTGTGGGGACAGG
GGTGTGGGG 
ILPR-1(2xG4)                
[Btn]ACAGGGGTGTGGGGACAGGGGTGTGGGGACAGGGGTGTGGG
GACAGGGGTGTGGGG  
Bcl-2                              
[Btn]GGGCGCGGGAGGAAGGGGG
CGG 
c-Myc(Pu27)                
[Btn]TGGGGAGGGTGGGGAGGGTGGGGAAGG 
VEGF                             
[Btn]GGGCGGGCCGGGGGCGGG 
c-Kit21                           
[Btn]GGGCGGGCGCGAGGGAGGG 
ILPR-2                             
[Btn]ACAGGGGTCTGGGGACAGGG
GTCTGGGG 
ILPR-3                             
[Btn]AGAGGGGTCTGGGGAGAGGGGTCTGGGG 
ILPR-4                            
[Btn]ATAGGGGTGTGTGGATAGGG
GTGTGTGG 
 
 
Table 1: The above table shows all oligos adopted in the gel-based assays, with sequences being shown in a 
5’ to 3’ orientation.  [Btn], biotin label covalently linked to 5’ end of each oligo. 
 
Initially preliminary tests were made to assess the ability of oligonucleotides to 
modify its conformation. 
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Figure 30: The EMSA intramolecular G-quadruplex structures of TEL.(2xG4), TEL.(1xG4), ILPR-1(2xG4), ILPR-1(1xG4).  1: 
1μl [10ηM] ILPR-1(1xG4) + 8μl TE + 1μl KCl; 2: 1μl [10ηM] ILPR-1(1xG4) + 9μl TE; 3: 1μl [10ηM] ILPR-1(1xG4) + 9μl TE*; 4: 
1μl [10ηM] ILPR-1(2xG4) + 8μl TE + 1μl KCl; 5: 1μl [10ηM] ILPR-1(2xG4) + 9μl TE; 6: 1μl [10ηM] ILPR-1(2xG4) + 9μl TE*; 7: 
1μl [10ηM] TEL.(1xG4) + 8μl TE + 1μl KCl; 8: 1μl [10ηM] TEL.(1xG4) + 9μl TE; 9: 1μl [10ηM] TEL.(1xG4) + 9μl TE*; 10: 1μl 
[10ηM] TEL.(2xG4) + 8μl TE + 1μl KCl; 11: 1μl [10ηM] TEL.(2xG4) + 9μl TE; 12: 1μl [10ηM] TEL.(2xG4) + 9μl TE 
*: only heated at 95 degree for 5 minutes 
 
Figure 31: The EMSA intramolecular G-quadruplex structures of C-Myc(Pu27), VEGF, c-Kit21, Bcl-2.  
1: 1μl [10ηM] c-MYC(Pu27)+ 8μl TE + 1μl KCl; 2: 1μl [10ηM] c-MYC(Pu27)+ 9μl TE; 3: 1μl [10ηM] c-MYC(Pu27) + 9μl TE*;  
4: 1μl [10ηM] VEGF + 8μl TE + 1μl KCl; 5: 1μl [10ηM] VEGF + 9μl TE; 6: 1μl [10ηM] VEGF + 9μl TE*; 7: 1μl [10ηM] c-Kit21+ 
8μl TE + 1μl KCl; 8: 1μl [10ηM] c-Kit21 + 9μl TE; 9: 1μl [10ηM] c-Kit21 + 9μl TE*; 10: 1μl [10ηM] Bcl-2 + 8μl TE + 1μl KCl;  
11: 1μl [10ηM] Bcl-2 + 9μl TE; 12: 1μl [10ηM] Bcl-2 + 9μl TE* 
*: only heated at 95 degree for 5 minutes 
 
Tel.(2xG4), Tel.(2xG4), ILPR-1(2xG4), ILPR-1(1xG4) 
c-Myc(Pu27), VEGF, c-kit21, Bcl-2 
                       1    2      3      4    5     6    7     8     9   10  11   12 
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Subsequently, the oligonucleotides of most interest were evaluated with the 
addition of a chemical compounds commercially available and known in the 
literature as stabilizers of the G-quadruplex. 
 
TMPyP4 tosylate  5,10,15,20-Tetrakis(1-methylpyridinium-4-yl)porphyrin tetra(p-
toluensulfonate) 
 
 
 
 
 
 
 
 
 
 
  
 
 
N
N HN
NH N
N
N N
S
O
OO
4
Figure 32: The EMSA intramolecular G-quadruplex structures of ILPR-2, ILPR-3, ILPR-4, ILPR-1(2xG4). 1: 1μl [10ηM] ILPR-
2 + 8μl TE + 1μl KCl; 2: 1μl [10ηM] ILPR-2+ 9μl TE; 3: 1μl [10ηM] ILPR-2 + 9μl TE*; 4: 1μl [10ηM] ILPR-3 + 8μl TE + 1μl KCl; 
5: 1μl [10ηM] ILPR-3 + 9μl TE; 6: 1μl [10ηM] ILPR-3 + 9μl TE*; 7: 1μl [10ηM] ILPR-4+ 8μl TE + 1μl KCl;                                      
8: 1μl [10ηM] ILPR-4 + 9μl TE; 9: 1μl [10ηM] ILPR-4 + 9μl TE*; 10: 1μl [10ηM] ILPR-1(2xG4) + 8μl TE + 1μl KCl;  
11: 1μl [10ηM] ILPR-1(2xG4) + 9μl TE; 12: 1μl [10ηM] ILPR-1(2xG4) + 9μl TE* 
 *: only heated at 95 degree for 5 minutes 
 
ILPR-2, ILPR-3, ILPR-4, ILPR-1(2xG4) 
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Figure 34: The EMSA intramolecular G-quadruplex structures of ILPR-1(2xG4); Bcl-2;c-Myc(Pu27) with TMPyP4 tosylate. 
1: 1μl ddH2O + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 2: 1μl [1μM] TMPyP4 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl 
KCl; 3: 1μl [2.5μM] TMPyP4 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 4: 1μl [5μM] TMPyP4 + 1μl [10ηM] ILPR-1(2xG4) 
+ 7μl TE  + 1μl KCl; 5: 1μl ddH2O + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 6: 1μl [1μM] TMPyP4 + 1μl [10ηM] Bcl-2 + 7μl TE  + 
1μl KCl; 7: 1μl [2.5μM] TMPyP4 + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 8: 1μl [5μM] TMPyP4 + 1μl [10ηM] Bcl-2 + 7μl TE  + 
1μl KCl; 9: 1μl ddH2O + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 10: 1μl [1μM] TMPyP4 + 1μl [10ηM] c-Myc(Pu27) + 7μl 
TE  + 1μl KCl; 11: 1μl [2.5μM] TMPyP4 + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 12: 1μl [5μM] TMPyP4 + 1μl [10ηM] c-
Myc(Pu27) + 7μl TE  + 1μl KCl 
 
Figure 33: The EMSA intramolecular G-quadruplex structures of ILPR-1(1xG4) with different concentration of TMPyP4 
tosylate. 1: 1μl ddH2O + 1μl [10ηM] ILPR-1(1xG4) + 8μl TE*; 2: 1μl ddH2O  + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 3: 
1μl [0.5μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 4: 1μl [1μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl 
TE  + 1μl KCl; 5: 1μl [2.5μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 6: 1μl [5μM] TMPyP4 + 1μl [10ηM] 
ILPR-1(1xG4) + 7μl TE  + 1μl KCl                                            
*: only heated at 95 degree for 5 minutes 
 
ILPR-1(2xG4), Bcl-2, c-Myc(Pu27) with TMPyP4 tosylate 
ILPR-1(1xG4) with different concentration of TMPyP4  tosylate 
                1             2          3            4             5               6 
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Mesoporphyrin IX dihydrochloride  
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Figure 35: The EMSA intramolecular G-quadruplex structures of ILPR-1(1xG4) with different concentration of chemical TMPyP4 tosylate. 1: 1μl 
ddH2O + 1μl [10ηM] ILPR-1(1xG4) + 8μl TE*; 2: 1μl v  + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 3: 1μl [0.001μM] TMPyP4 + 1μl [10ηM] 
ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 4: 1μl [0.005μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 5: 1μl [0.01μM] TMPyP4 + 1μl 
[10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 6: 1μl [0.05μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 7: 1μl [0. 1μM] TMPyP4 + 
1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 8: 1μl [0.25μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl;                                        
9: 1μl [0.5μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 10: 1μl [1μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 
11: 1μl [2.5μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 12: 1μl [5μM] TMPyP4 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl 
*: only heated at 95 degree for 5 minutes 
 
ILPR-1(1xG4) with different concentration of TMPyP4 tosylate 
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Figure 36: The EMSA intramolecular G-quadruplex structures of ILPR-1(1xG4) with different concentration of chemical Mesoporphyrin IX 
dihydrochloride. 1: 1μl ddH2O + 1μl [10ηM] ILPR-1(1xG4) + 8μl TE*; 2: 1μl ddH2O + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 3: 1μl 
[0.001μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 4: 1μl [0.005μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  
+ 1μl KCl; 5: 1μl [0.01μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 6: 1μl [0.05μM] Mesoporphyrin + 1μl [10ηM] ILPR-
1(1xG4) + 7μl TE  + 1μl KCl; 7: 1μl [0. 1μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 8: 1μl [0.25μM] Mesoporphyrin + 
1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 9: 1μl [0.5μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 10: 1μl [1μM] 
Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 
12: 1μl [5μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl                                
 *: only heated at 95 degree for 5 minutes 
 
Figure 37: The EMSA intramolecular G-quadruplex structures of ILPR-1(2xG4); Bcl-2;c-Myc(Pu27) with different concentration of chemical 
Mesoporphyrin IX dihydrochloride. 
1: 1μl ddH2O+ 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 2: 1μl [1μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 3: 1μl 
[2.5μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 4: 1μl [5μM] Mesoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl 
KCl; 5: 1μl ddH2O + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 6: 1μl [1μM] Mesoporphyrin + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 7: 1μl [2.5μM] 
Mesoporphyrin + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 8: 1μl [5μM] Mesoporphyrin + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 9: 1μl ddH2O + 1μl 
[10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 10: 1μl [1μM] Mesoporphyrin + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] 
Mesoporphyrin + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 12: 1μl [5μM] Mesoporphyrin + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl 
 
ILPR-1(1xG4) with diferent concentration of Mesoporphyrin 
IX Dihydrochloride 
ILPR-1(2xG4), Bcl-2, c-Myc(Pu27) with Mesoporphyrin IX 
Dihydrochloride 
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Protoporphyrin IX 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation the best concentrations of porphyrin. 
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Figure 38: The EMSA intramolecular G-quadruplex structures of three series of ILPR-1(2xG4) with different concentration of chemical 
Protoporphyrin IX. 1: 1μl ddH2O  + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 2: 1μl [1μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl 
TE  + 1μl KCl; 3:1μl [2.5μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 4: 1μl [5μM] Protoporphyrin + 1μl [10ηM] ILPR-
1(2xG4) + 7μl TE  + 1μl KCl; 6: 1μl [1μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 7: 1μl [2.5μM] Protoporphyrin + 1μl 
[10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 8: 1μl [5μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl;  
10: 1μl [1μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl 
TE  + 1μl KCl; 12: 1μl [5μM] Protoporphyrin + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl 
5, 9 are gap. 
 
3 times of ILPR-1(2xG4) with Protoporphyrin IX 
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Figure 39: The EMSA  intramolecular G-quadruplex structures of ILPR-1(1xG4); Bcl-2;c-Myc(Pu27). 1:1μl ddH2O + 1μl [10ηM] ILPR-1(1xG4) + 
7μl TE  + 1μl KCl; 2: 1μl [1μM] Protoporphyrin + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 3: 1μl [2.5μM] Protoporphyrin  + 1μl [10ηM] 
ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 4: 1μl [5μM] Protoporphyrin  + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 5:  1μl ddH2O + 1μl [10ηM] Bcl-2 
+ 7μl TE  + 1μl KCl; 6: 1μl [1μM] Protoporphyrin + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 7: 1μl [2.5μM] Protoporphyrin  + 1μl [10ηM] Bcl-2 + 7μl 
TE  + 1μl KCl; 8: 1μl [5μM] Protoporphyrin  + 1μl [10ηM] Bcl-2 + 7μl TE  + 1μl KCl; 9: : 1μl ddH2O + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 
10: 1μl [1μM] Protoporphyrin  + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] Protoporphyrin  + 1μl [10ηM] c-Myc(Pu27) + 7μl 
TE  + 1μl KCl; 12: 1μl [5μM] Protoporphyrin + 1μl [10ηM] c-Myc(Pu27) + 7μl TE  + 1μl KCl 
 
ILPR-1(1xG4), Bcl-2, c-Myc(Pu27) with Protoporphyrin IX 
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4.5 Synthesis of a new compound triazole derivate 
Synthesis of Benzyltriethylammonium dichloroiodate (9) 
 
 
 
 
 
 
 
 
To a stirred solution of ICl (1.5 g, 9.2 mmol) in 20 ml of DCM was added BnEt3NCl 
(2.1 g, 9.2 mmol) in 10 ml of water via an addition funnel over 15 minutes. After 
stirring for 30/40 minutes the layers were separated, and the organic layer was 
dried (MgSO4), filtered and concentrated under reduced pressure. The residue 
was crystallized by taking it up in minimal DCM and back adding Et2O to 3:1 
(DCM:Et2O) ratio. It was left overnight (o.n.). After the material was filtered and 
washed many times with Et2O and dried under vacuum to afford 2.9 g (Y=91%) of 
yellow crystals. 
1H NMR (400 MHz, d6-DMSO):  7.57 - 7.50 (m, 5H), 4.48 (s, 2H), 3.16 (q, J = 7.2 
Hz, 6H), 1.31 (t, J = 7.2Hz,9H). 
 
 
N
CH3
CH3
CH3
Cl
ICl C13H22Cl2IN 
Mol. Wt.: 390,1 
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Synthesis of 4- Tert- butyl-2,6-diiodo-phenylamine (2) 
 
 
 
 
 
 
 
 
To a stirred solution of t-butyl aniline (306 mg, 2.04 mmol) in DCM (27.2 ml) and 
MeOH (13.6 ml) BnEt3NICl2 (1.5 g, 4.3 mmol) and CaCO3 (817 mg, 8.2 mmol) 
were added. The reaction was stirred at 40°C on. After the reaction was monitored 
via TLC  9.5:0.5 (Hexane:AcOEt). It was filtered through a bed of celite and 
concentrated to 1/3 the volume. The organic phase was washed with 5% NaHSO3, 
sat NaHCO3, water and brine. The organic layer was dried (MgSO4), filtered and 
concentrated to give a red oil. The material was purified using flash 
chromatography (SiO2) 9.8:0.2 (Hexane:AcOEt) to afford 408 mg (Y=50%) of a 
dark brown oil. 
 1H NMR (400 MHz, CDCl3):  7.64 (s, 2H), 4.49 (s, 2H), 1.26 (s, 9H).  
 
I I
NH2
C10H13I2N 
Mol. Wt.: 401,0 
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Synthesis of 1-Tert- butyl-3,5-diiodo-benzene (3) 
 
 
 
 
 
 
To a stirred solution of DMF (1.2 ml) at 60°C was added t-butylnitrite(210 mg, 2.03 
mmol) followed by 4-tert-Butyl-2,6-diiodo-phenylamine (408 mg, 1.02 mmol) in 581 
µl of DMF dropwise (*Note to resume the product in the flask it was used about 1 
ml of  DMF). After stirring for 10 minutes, the reaction was allowed to cool, diluted 
with AcOEt (48 ml) and water (48 ml). The organic layer was washed with brine, 
dried over MgSO4, filtered and concentrated. TLC Hexane. The material was 
purified using flash chromatography (SiO2) 100% (Hexane) to afford 364 mg 
(Y=92%) of a solid pink clear63. 
1H NMR (400 MHz, CDCl3):  7.89 (t, J = 1.5 Hz, 1H), 7.67 (d, J = 1.5 Hz, 2H), 
1.32 – 1.27 (m, 9H). 
 
 
 
C10H12I2 
Mol. Wt.: 386,0 
I I
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Synthesis of 3-iodo-1-tert-butyl-5-(trimethylsilylethynil)benzene (4) 
 
 
 
 
 
 
 
 
3,5-Diiodo-1-tert-butyl-benzene (155 mg,0.4 mmol), CuI (1.5 mg, 0.008 mmol) and 
Pd(PPh3)Cl2 (5.6 mg, 0.008 mmol) were placed in a two neck flask, wich was 
degassed under high vacuum and back-filled with Nitrogen three times. Degassed 
THF (5 ml) and LDA (1 ml) were added followed by the dropwise addition of 
Ethynyltrimethylsilane (TMS) (19.6 mg, 0.2 mmol). The reaction mixture was 
stirred o.n. at r.t.. The reaction was checked by TLC 100%( Hexane). The volatiles 
were removed in vacuum and the yellow solid obtained was washed with water 
and exctracted with CH2Cl2 (three times), dried with MgSO4 and concentrated 
under reduced pressure. Flash chromatography (SiO2) 100% (Hexane) to afford 
83.4 mg of compound 4 (Y= 59%). 
1H NMR (400 MHz, CDCl3):  7.66 (dt, J = 4.2, 1.7 Hz, 2H), 7.46 – 7.43 (m, 1H), 
1.30 (s, 9H), 0.28 – 0.26 (m, 9H). 
 
 
C15H21ISi 
Mol. Wt.: 356,3 
I
Si
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Synthesis of 3-iodo-5-ethynil-1-tert-butylbenzene (5) 
 
 
 
 
 
A 50 ml flask was charged with 3-iodo-1- tert-butyl-5-(trimethylsilylethynil)benzene 
(163.2 mg, 0.458 mmol), KF (133 mg, 2.29 mmol), THF (1.64 ml) and methanol 
(1.64 ml) and stirred at r.t. for 8 h. The volatiles were removed in vacuo and the 
solid obtained was extracted with CH2Cl2 and water (the last wash with brine), 
dried with MgSO4 and concentrated under pressure. Purification by preparative 
TLC 9.8:0.1 (CH2Cl2:Hexane) to afford 130 mg of compound 5 (Y= 34%).  
1H NMR (400 MHz, CDCl3):  7.71 (t, J=1.7 Hz, 1H), 7.68 (t, J=1.5 Hz, 1H), 7.49 
(t, J=1.6 Hz, 1H), 3.11 (s, 1H), 1.31 (d, J=1.9 Hz, 9H). 
 
 
 
 
 
 
 
I
H
C12H13I 
Mol. Wt.: 284,1 
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Synthesis of 3,5-diazido-1-tert-butylbenzene (6) 
 
 
 
 
 
 
3,5-Diiodo-1-tert-butylbenzene (220 mg, 0.57 mmol), NaN3 (111 mg, 1.71 mmol), 
sodium ascorbate (11.3 mg, 0.057 mmol), DMEA (15 mg, 0.171 mmol) were 
added to degassed solvent mixture EtOH:H2O:toluene (7:3:1, 3 ml). The reaction 
was followed by TLC. 
When the 3,5-Diiodo-1-tert-butylbenzene was completely consumed (about 1h), 
the reaction mixture was allowed to cool down to r.t.. The reaction goes to 
completeness and it was formed only azide to afford 88 mg (Y= 71%). 
 1H NMR (400 MHz, CDCl3):  6.82 (d, J = 2.0 Hz, 2H), 6.53 (t, J = 2.0 Hz, 1H), 
1.32 (s, 9H). 
 
 
 
 
 
N3 N3
C10H12N6 
Mol. Wt.: 216,2 
Aberdeen’s project                                                                                            Experimental section 
 179 
Synthesis of 1,1'-(5-(tert-butyl)-1,3-phenylene)bis(4-(3-(tert-butyl)-5-iodophenyl)-
1H-1,2,3-triazole) (7) 
 
 
 
 
 
 
 
 
 
 
A solution of the diazide (15.32 mg, 0.0709 mmol), and monoacetylene (44.3 mg, 
0.156 mmol), sodium ascorbate (1.4 mg, 0.00709 mmol) and CuSO4 (0.11mg; 
0.000709 mmol) in 7:3:1 mixture of EtOH:H2O:Toluene (993 µl) was stirred at r.t. 
for 24h with N2.  Flash chromatography (SiO2) 9:1 (Hexane:AcOEt) to afford 44.8 
mg of compound 764 (Y= 81%). 
1H NMR (400 MHz, CDCl3):  8.31 (s, 2H), 8.08 (m,  J=1.6 Hz, 3H), 7.96 (t, J= 1.6 
Hz, 2H), 7.93 (t, J=1.6 Hz, 2H), 7.93 (d, J=2 Hz, 2H), 7.74 (t, J=1.7 Hz, 2H), 1.49 
(s, 9H),1.38 (s,18H). 
 
MS (ESI): [M+H]+= 784.12 
 
 
N
N
NN
N
N
II
C34H38I2N6 
Mol. Wt.: 784,5 
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ZAL026 Synthesis of 6,6'-((1,1'-(5-(tert-butyl)-1,3-phenylene)bis(1H-1,2,3-triazole-
4,1-diyl))bis(3-(tert-butyl)-5,1-phenylene))bis(2-methoxypyridine) (8) 
 
 
 
 
 
 
 
 
 
 
 
In a very small flask was degassed under high vacuum and back-filled with N2  
three times. 
1,1'-(5-(tert-butyl)-1,3-phenylene)bis(4-(3-(tert-butyl)-5-iodophenyl)-1H-1,2,3-
triazole) (20 mg, 0.0026 mmol), CsF (15.5 mg, 0.102 mmol), Pd(PPh3)4 (3 mg, 
0.0026 mmol)  and the 2-methoxy-6-(tributylstannyl)pyridine (22.3 mg, 0.056 
mmol) were dissolved in a minimum amount of CH3CN (2 ml). The reaction 
mixture was stirred at 90 °C o.n.. DMF dried was added (1 ml). The reaction was 
checked by TLC. The volatiles were removed in vacuum and the liquid obtained 
was filtered through a bed of celite, washed with brine and extracted with CH2Cl2, 
dried with MgSO4 and concentrated under pressure. Purification by preparative 
TLC 8:2 (Hexane:AcOEt) to afford 7.8 mg of ZAL026 (Y= 52%). 
1H NMR (400 MHz, CDCl3):  8.40 – 8.36 (m, 4H), 8.14 (dt, J = 8.7, 1.8 Hz, 3H), 
8.03 (t, J = 1.7 Hz, 2H), 7.97 (d, J = 1.9 Hz, 2H), 7.71 – 7.65 (m, 2H), 7.47 – 7.44 
(m, 2H), 6.74 (d, J = 8.1 Hz, 2H), 4.09 (s, 6H), 1.50 (s, 9H), 1.47 (s, 18H). 
 
13C NMR (100 MHz, CDCl3):  163.83, 155.88, 154.82. 152.39, 149.23, 139.69, 
139.25, 138.0, 130.02, 124.40, 123.64, 121.77, 117.88, 117.73, 113.27, 109.31, 
53.32, 35.06, 31.43, 31.22, 29.70, 27.85, 26.85, 17.53, 13.61, 13.56. 
 
MS (ESI): [M+H]+= 746.942 
C46H50N8O2 
Mol. Wt.: 746,9 
N
N
NN
N
N
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Finally this compound it was tested with EMSA like porphyrin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N
NN
N
N
NN
O O
Figure 40: The EMSA intramolecular G-quadruplex structures of c-Myc with different concentration of chemical ZAL026. 1: 1μl ddH2O + 1μl 
[10ηM] c-Myc+ 8μl TE*; 2: 1μl ddH2O  + 1μl [10ηM] c-Myc+ 7μl TE  + 1μl KCl; 3: 1μl [0.001μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 
4: 1μl [0.005μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 5: 1μl [0.01μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 6: 1μl 
[0.05μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 7: 1μl [0. 1μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl;                                           
8: 1μl [0.25μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 9: 1μl [0.5μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 10: 1μl [1μM] 
ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] ZAL026 + 1μl [10ηM] c-Myc + 7μl TE  + 1μl KCl; 12: 1μl [5μM] ZAL026 + 1μl 
[10ηM] c-Myc + 7μl TE  + 1μl KCl                                              
*: only heated at 95 degree for 5 minutes 
 
c-Myc(Pu27) with different concentration of ZAL026 
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Figure 41: The EMSA intramolecular G-quadruplex structures of ILPR-1(1xG4) with different concentration of chemical ZAL026. 
1: 1μl ddH2O + 1μl [10ηM] ILPR-1(1xG4) + 8μl TE*; 2: 1μl ddH2O  + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl;  3: 1μl [0.001μM] ZAL026 + 
1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl;  4: 1μl [0.005μM] ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 5: 1μl [0.01μM] 
ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 6: 1μl [0.05μM] ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 7: 1μl [0. 1μM] 
ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 8: 1μl [0.25μM] ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 9: 1μl [0.5μM] 
ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 10: 1μl [1μM] ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] 
ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl; 12: 1μl [5μM] ZAL026 + 1μl [10ηM] ILPR-1(1xG4) + 7μl TE  + 1μl KCl 
*: only heated at 95 degree for 5 minutes 
 
Figure 42: The EMSA intramolecular G-quadruplex structures of ILPR-1(2xG4) with different concentration of chemical ZAL026. 1: 1μl ddH2O + 
1μl [10ηM] ILPR-1(2xG4) + 8μl TE*; 2: 1μl ddH2O  + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 3: 1μl [0.001μM] ZAL026 + 1μl [10ηM] ILPR-
1(2xG4) + 7μl TE  + 1μl KCl; 4: 1μl [0.005μM] ZAL026 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 5: 1μl [0.01μM] ZAL026 + 1μl [10ηM] 
ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 6: 1μl [0.05μM] ZAL026 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 7: 1μl [0. 1μM] ZAL026 + 1μl [10ηM] 
ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 8: 1μl [0.25μM] ZAL026 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 9: 1μl [0.5μM] ZAL026 + 1μl [10ηM] 
ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 10: 1μl [1μM] ZAL026 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 11: 1μl [2.5μM] ZAL026 + 1μl [10ηM] 
ILPR-1(2xG4) + 7μl TE  + 1μl KCl; 12: 1μl [5μM] ZAL026 + 1μl [10ηM] ILPR-1(2xG4) + 7μl TE  + 1μl KCl 
*: only heated at 95 degree for 5 minutes 
 
ILPR-1(1xG4) with different concentration of ZAL026 
ILPR-1(2xG4) with different concentration of ZAL026 
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4.6 Circular Dichroism 
Circular dichroism (CD) refers to the differential absorption of left and right 
circularly polarized light. It is exhibited in the absorption bands of optically active 
chiral molecules. CD spectroscopy has a wide range of applications in many 
different fields.  UV CD is used to investigate the secondary structure of proteins 
and to monitor the effects of chemical modification on quadruplex structure. The 
absorbance hypochromicity of quadruplex DNAs is inclined to be much smaller 
than that associated with duplex DNA65.  
It seems in some type of DNA oligonucleotide that Na+ induces an intramolecular 
basket-type G-quadruplex complex, while in presence of K+ forms an 
intramolecular propeller-type G-quadruplex can be formed59.  
There are four principal conformations of DNA quadruplex (Figure 42). 
 
Figure 43: Possible structures of G quadruplex. 
 
 
 
 
 
                                                        
65
 S. Paramasivan, I. Rujan, P. H. Bolton, Methods, (2007), 43, 324-331. 
Anti-parallel structures  
Parallel structures  
A. Lateral loops, chair type structure B. Diagonal loops, basket type structure  
C. Four stranded parallel structure D. External loops, propeller type 
structure  
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Figure 44: CD spectra of the four different types. 
 
Structures 
Characteristics wavelength 
Positive(+)                                  Negative(-) 
A. Lateral loops, chair type 
structure 
 
210 nm, 240nm, 290nm 260 nm 
B. Diagonal loops, basket 
type structure 
 
210 nm (broad signal), 
232nm, 245nm, 290nm 
262 nm 
C. Four stranded parallel 
structure 
 
210 nm, 262 nm 240 nm 
D. External loops, propeller 
type structure 
 
260 nm, 290 nm 230 nm 
 
Table 2: Wavelengths of different type of structures. 
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